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Abstract and Keywords

Dietary and gastrointestinal factors may be associated w ith the
developm ent/w orsening of autistic sym ptom s in a subset of patients. Propionic
acid (PPA) is a m etabolic byproduct of gut bacterial ferm entation.
Intracerebroventricular (ICV) infusions of PPA in rodents produce tran sien t
behavioural and biochem ical changes sim ilar to those seen in autism. The
perm anence of the cognitive deficits associated w ith the PPA ro d en t m odel of
autism w as assessed using adult male rats in the Morris w a ter m aze (MWM).
Following an ICV regim en of PPA or vehicle (2x/day, 7 days), rats w ere tested in the
MWM (acquisition) and then one w eek later for reversal. On reversal day,
perseveratory behaviours w ere assessed following 2 additional infusions. PPAS

treated rats displayed longer search latencies to find the platform during MWM
acquisition, b u t show ed norm al reversal one w eek later. A second experim ent used
nonspatial pretrain in g p rio r to treatm en t in order to differentiate betw een spatial
versus strategy deficits, and effects of stress in the MWM. Similar to the first study,
rats treated w ith PPA on reversal day show ed im pairm ents in the maze, regardless
of initial drug treatm ent. In sum m ary, PPA treatm en t caused im pairm ents in
cognition as m easured in the MWM, but these behavioural im pairm ents appear to
retu rn to baseline after the drug trea tm e n t is stopped, suggesting th a t some effects
of PPA m ay be reversible.
Keywords: autism spectrum disorder, animal model, Morris w a ter maze, propionic
acid
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Chapter 1

G eneral Introduction
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2
1.1 Autism Spectrum Disorders
Autism spectrum disorders (ASDs) are a family o f neurodevelopmental disorders
affecting approximately 1 in 110 children (Centers for Disease Control & Prevention,
2009). This family o f disorders is characterized by social deficits, profound language and
communication impairments, repetitive and ritualistic behaviours, sensory disturbances,
and altered motor activity (Arndt, Stodgell, & Rodier, 2005; DiCicco-Bloom, et al., 2006).
As well, there is an increased occurrence o f seizure disorder in individuals with ASD
(Besag, 2004). Learning has also been shown to be disrupted in autistic individuals.
Mostofsky et al. (2000) reported impaired ability to acquire procedural knowledge in
autistic participants, whereas other aspects of performance on a serial response time task,
such as judgement o f timing intervals, were no different than control children. Similarly,
it has been shown that individuals with autism are equally able to discriminate between
novel and familiar stimuli, while control participants were better able to discriminate
familiar stimuli as opposed to novel stimuli (Plaisted, O’Riordan, & Baron-Cohen, 1998).
It has been suggested that autistic individuals tend to show increased attentional focus on
specific stimuli and that perhaps this leads to the selection o f only a small subset of the
environmental stimuli on which these individuals base their responding (Plaisted et al.,
1998). Finally, Schipul and colleagues (2011) examined the functional connectivity in the
brains o f ASD patients and suggested the possibility that the impairments in the ability of
individuals with autism to rapidly adapt during learning could be the result of cortical
underconnectivity. Together, these findings point towards impaired learning in ASD, with
an emphasis on increased attention to specific stimuli and lack of ability to adapt to novel
stimuli.

3
Beyond the behavioural aspect o f the disorder, there are also consistent
developmental abnormalities seen in the brains of individuals with autism. Specifically,
during the first few years o f life, children with autism show increased brain sizes
compared to controls (Bauman & Kemper, 2005; Herbert, 2005; Herbert et al., 2005).
This increase in overall size appears to be linked to a disproportionate increase in white
matter that occurs beginning shortly after birth arid returns to control levels after several
years, such that only younger autistic brains are larger than controls. The increase in white
matter, as well as the nonuniform pattern in which this occurs, appears to be suggestive of
postnatal pathology (Herbert, 2005). Similarly, examination o f brain tissue of ASD
patients has shown evidence o f an innate neuroinflammatory response, including activated
microglia, reactive astrogliosis, and increased levels o f proinflammatory cytokines found
in the cerebral spinal fluid o f these individuals (Vargas, Nascimbene, Krishnan,
\
Zimmerman, & Pardo, 2005). While the number o f neurons in the brains of autistic
patients appears to be the same as what is seen in healthy control brains, an increase in
neuronal density is observed in certain areas, including neocortical, limbic, and cerebellar

v
areas (Cody, Pelphrey, & Piven, 2002; Courchesne & Pierce, 2005).
Studies have shown that concordance rates for autism in monozygotic twins are
between 60% and 90%, as opposed to 0-10% concordance in dizygotic twins (Bailey et al.,
1995; Steffenburg et al., 1989). Similarly, there is also a discrepancy in the severity of the
disorder in monozygotic twins. This incomplete concordance rate, along with the
increasing prevalence o f autism over the past several decades, has suggested the
possibility o f an environmental contribution to the pathogenesis o f autism. Many
epidemiological models have focused on potential neonatal or early postnatal

environmental factors, such as exposure to valproic acid (Ingram, Peckham, Tisdale, &
Rodier, 2000),' ethanol (Arndt, Stodgell, & Rodier, 2005), and thalidomide (Narita, Kato,
Tazoe, Miyazaki, Narita, & Okado, 2002). Also, exposure to several types o f metals or

i
viral infections have been implicated as potential factors (Curtis, Hood, Chen, Cobb, &
Wallace; 2010; Fatemi, Cuadra, El Fakahany, Sidwell, & Thuras, 2000). Based on this,
ASD is now considered to be a whole-body condition involving immune, digestive, and

/

/

metabolic dysfunction, all o f which can be triggered by these environmental factors in
genetically susceptible individuals (Ashwood & Van de Water, 2004; Chauhan &
Chauhan, 2006; Herbert et al., 2006; Horvath & Perman, 2002).
Gastrointestinal (GI) disturbances have also been reported in autism, with findings
that up to 59% o f autistic patients suffer from some sort o f GI dysfunction, including
diarrhea, constipation, bloating, and gastroesophageal reflux (Adams, Johansen, Powell,
'

'

.

\

Quig, & Rubin, 2011; Ming, Brimacombe, Chaaban, Zimmerman-Bier, &W agner, 2008).
Reports of the development and/or worsening o f autistic symptoms following such
gastrointestinal abnormalities (Adams, Johansen, Powell, Quig, & Rubin, 2011; Horvath,
Papadimitrou, Rabsztyn, Drachenberg, & Tildon, 1999), the ingestion o f certain types of
i carbohydrates and dairy products, and pediatric infections for which antibiotics are
administered (Goodwin, Cowen, & Goodwin, 1971; Finegold, Song, & Liu, 2002; Fallon,
2005) also provide some support for the involvement o f environmental agents in the
development o f autism in susceptible individuals.
1.1.1 Gastrointestinal and Digestive Dysfunction
GI difficulties are present in a large subset o f children with ASD. These
abnormalities include various different symptoms and have been shown to be present
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significantly more in autistic children than normally developing children (Adams et al.,
2011). Finegold et al. (2002) analyzed the fecal flora from children with late-onset autism
as well as healthy control children and found higher levels o f Clostridium and
Ruminococcus species, as well as a greater number of these types o f species, in the stools
o f autistic children. Specifically, Finegold and colleagues (2002) reported the presence of
nine species o f Clostridia found in ASD patients that were not found in controls, whereas
there were only three species found in controls that were not present in individuals with
ASD. Clostridia are the principal bacteria that produce enterotoxins and neurotoxins.
This, along with their high metabolic activity, allows them to produce potentially high
levels o f toxic metabolites which can influence the central nervous system (Finegold et al.,
2002). Treatment with antibiotics, rather than eradicating these types o f bacteria, which
can be difficult due to the spore-forming nature o f Clostridia, can in fact promote
\

overgrowth o f certain bacterial species (Finegold et al., 2002). This is an important
finding given the putative association between antibiotic use and the occurrence of lateonset autism (Parracho, Bingham, Gibson, & McCartney, 2005). Recently, Finegold and
colleagues (2010) identified two additional types of enteric bacterial species that are
present in significantly higher numbers in children with ASD compared to controls. These
two types o f bacteria, Desulfovibrio species and Bacteroides vulgatus, also produce PPA
and other short-chain fatty acids (SCFAs) in the digestive system. Together, these findings
point towards significant alterations in the intestinal flora of ASD patients, which may be
involved in the development o f the disorder.
1.2 Propionic Acid
Propionic acid (PPA) is a short-chain fatty acid that is naturally present in the
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digestive systems o f many organisms. This compound serves an important function in the
gastrointestinal ecosystem, including anti-bacterial, anti-fungal, and anti-inflammatory
protective effects, as well as playing a role in some obesity-related diseases by lowering
cholesterol and increasing the duration of satiety (Al-Lahham, Peppelenbosch, Roelofsen,
Vonk, & Venema, 2010; Boden, 2008; Davidson, Sofos, & Branes, 2005; Levison, 1973).
Conversely, PPA also has several negative effects in the body, such as contributing to
gingival inflammation (Niederman, Zhang, & Kashket, 1997), reducing antioxidant
capacity (MacFabe et al., 2008), and interfering with fatty acid metabolism when present
in elevated levels (Akman, Imamoglu, Demirkol, Alpay, & Ozek, 2002; Thomas, Foley,
Mepham, Tichenoff, Possmayer, & MacFabe, 2010).
PPA is a metabolic by-product of fermentation in the gut. Interestingly,
approximately 20% o f the PPA present in the body is produced by ASD-associated enteric
bacteria (i.e., Clostridia, Desulfovibrio, etc.), as a result o f such fermentation (Finegold et
al., 2002; Finegold et al., 2010). PPA is a weak organic acid and is present in the blood in
both ionized and non-ionized forms, which allows it to gain access to the central nervous
system (CNS) by readily crossing lipid membranes such as the gut-blood barrier and the
blood-brain barrier (Niederman, Zhang, Kashket, 1997; Maurer, Canis, Kuschinsky, &
Duelli, 2004). Once PPA, as well as other short-chain fatty acids, have become
incorporated into the systemic or CNS environment, they have been shown to affect
several different physiological processes. These widespread effects include cell signaling
(Nakao, Moriya, Furuyama, Niederman, & Sugiy, 1998), mitochondrial function (Wagner,
Bayir, Ren, Puccio, Zafonte, & Kochanek, 2004), lipid metabolism (Hara, Haga, Aoyama,
& Kiriyama, 1999), neurotransmitter synthesis and release (DeCastro, et al., 2005),

immune function (Le Poul et al., 2003), modulation of gene expression (Suzuki, Nagao,
Tokunaga, Katayama, & Uyeda, 1996), and gap junctional gating (Rorig, Klausa, & Sutor,
1996). All o f these effects suggest that PPA could be involved in the various aspects of
ASD.

■.

■.

. ■

1.2.1 Propionic A cid & Autism
There are several metabolic conditions that are linked with elevated levels of PPA,
including propionic acidemia (Brusque et al., 1999; Wajner, Latini, Wyse, & Dutra-Filho,
2004). In this disorder, levels o f PPA are constantly elevated in the blood due to disrupted
metabolism o f the compound. Propionic acidemia is characterized by developmental
delay, seizure disorder, and GI difficulties, all of which are reminiscent of autistic
symptomatology (Brusque et al., 1999; Kaya et al., 2008), indicating that accumulation of
PPA can elicit autistic-like traits.

\

The ability o f PPA to induce autistic-like symptoms, as well as the elevated levels
of PP A-producing bacteria found in the intestinal tracts of ASD patients have lead to the
establishment o f the PPA rodent model o f autism.Mntracerebroventricular (ICV) infusions
o f PPA and related enteric short-chain fatty acids (i.e., butyrate, acetate) directly into the
lateral ventricle o f adult Long-Evans rats have led to behavioural findings including bouts
of hyperactivity, repetitive and stereotypical movements, object fixation, social
. impairments, kindling o f seizures, caudate spiking, and perseveration, all o f which are
consistent with traits seen in ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe,
Cain, Boon, Ossenkopp, & Cain, 2011; Shultz et al., 2008; Shultz et al., 2009). Similarly,
neuropathological and biochemical findings from this model give evidence of an innate
neuroinflammatory response, including reactive astrogliosis and activated microglia, as
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well as an increase in oxidative stress markers and a reduction in glutathione (MacFabe et
al., 2007; MacFabe et al., 2008). These data are again consistent with the innate immune
response and the increased oxidative stress found in ASD autopsy data (Chauhan,
Chauhan, Brown, & Cohen, 2004; Vargas et al., 2005; Chauhan & Chauhan, 2006; James
et al., 2006). Finally, the PPA rodent model o f autism has provided evidence of altered
lipid profiles, similar to what is seen in the human disorder (Bell, Sargent, Tocher, &
Dick, 2000; Clark-Taylor & Clark-Taylor, 2004). The alterations seen in the model
include both increases and decreases in certain species of fatty acids (e.g. increases in
saturated fatty acids, decreases in monounsaturated fatty acids, and alterations in the
balance o f the omega fatty acids), as well as altered carnitine and acylcamitine profiles.
These alterations have been shown in lipids involved in cell-to-cell signaling, membrane
fluidity, and mitochondrial energy metabolism (Thomas et al., 2010).
\'
As mentioned, seizure disorder is often comorbid with ASD (Besag, 2004; Sansa et
al., 2011). Autism is associated with an increased risk o f epilepsy, which includes a
variety o f seizure types, and 6-60% o f autistic patients demonstrate epileptiform
abnormalities on electroencephalogram (EEG; Hara, 2007; Sansa et al., 2011). In
addition, the prevalence o f seizure disorder in autism increases with several factors, one of
which is decreased intellectual disability. The mechanisms involved in the increased
occurrence o f seizure disorder in ASD are relatively unknown. Several PPA-dependent
mechanisms could produce seizure, including interruptions in gap junctional
communication, GABAergic inhibition, and potentiation of glutamate receptors (MacFabe
et al., 2007). Taken together, it has been shown that seizure is a common aspect of ASD
and thus it is important to consider seizure activity in the PPA rodent model.
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1.3

Clinical Fluctuation in Autistic Symptoms

While it is generally agreed upon that improvement may be seen in certain cases of
ASD, this type o f “recovery” has not been extensively studied. This controversial concept
o f worsening and improvement in autism has received attention both anecdotally and
experimentally (Mundy & Crowson, 1997; Dawson & Zanolli, 2003; Fein, Dixon, Paul, &
Levin, 2005). However, there are currently no suggested putative mechanisms by which
such fluctuations might be occurring, nor are there biomarkers that might help elucidate
the nature o f these fluctuations. Reports from parents with autistic children have indicated
that there is a link between ingestion o f certain dietary components, such as refined
carbohydrates or dairy products, which are often craved by these patients, and the
worsening o f autistic symptoms (Jyonouchi, Sun, & Itokazu, 2002). Conversely,
improvements in behaviour, social abilities, and GI function have been observed
empirically in some patients following treatment with antibiotics, administration of
antioxidants, facilitation o f mitochondrial function, or changes in diet (Horvath et al.,
1999). Herbert and colleagues (2006) noted that in autistic individuals there is substantial
\

intra-individual variability in both the nature and severity o f the characteristic symptoms,
which is not necessarily a result o f treatment. This variability has been found to occur
over the short, medium, or long term. These changes in autistic symptomatology suggest
that the idea o f “recovery” is an area that should be further explored. The concept of
“recovery” must be approached with caution, as there is no generally accepted definition
at this point in time. Helt et al. (2008) describe “recovery” as the loss o f the behavioural
characteristics o f ASD. They do not claim' however, that a child must be labeled

/ /

“normal” in order to be considered “recovered”.

Thus “recovery”, for the purposes of the

present studies, will be used to refer to a return to baseline levels o f performance.
1.4 Present Studies
Autism is a complex disorder with multiple factors contributing to its development
(Herbert el al., 2006). It has been suggested that ASD symptoms can follow a pattern o f :,
waxing and waning, depending on such external factors as dietary intake, GI disturbances,
or treatment with antibiotics, in a subset of patients. Given the association between gut
bacteria, the production o f SCFAs, and autistic symptomatology, it is necessary to look at
the time course o f PPA-induced behavioural and neuropathological characteristics in order
to examine this concept o f clinical fluctuation in an animal model. PPA has been shown
to cause alterations in several aspects of cognition, including learning and memory
(Brusque et al., 1999; MacFabe et al., 2007; MacFabe et al., 2011; Shultz et al., 2009).
\

Given the known impairments in both learning and memory experienced by individuals
J
with autism, including deficits in visual recognition memory (Boucher & Warrington,
1976), it was important to investigate the effects o f PPA on learning and memory in the
rodent model. Recently, MacFabe and colleagues (2011) showed an increased amount of
time spent interacting with a specific, preferred object by PPA-treated rats compared to
■■
r
controls. Similarly, these same PPA-treated rats spent less time than controls approaching
and interacting with a novel rat in an open field, when given the choice between a novel
^ •
rat and a hovel object. It was concluded that PPA treatment can cause animals to
i

perseverate on a specific object, which is consistent with the repetitive and ritualistic
behaviours seen in ASD patients (Sasson, Turner-Brown, Holtzclaw, Lam, & Bodfish,
2008). The present experiments were designed to assess the long-term effects of PPA on
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the cognitive abilities o f adult male rats, as measured in the Morris water maze. The
Morris water maze is a common test of spatial learning and memory in behavioural
neuroscience. Rodents are given a certain number of training trials in a circular pool filled
with water to learn the location o f a hidden platform, based on visual cues around the
room. This is called acquisition o f the maze and occurred immediately following infusion.
Given that the half life o f PPA has been shown to be between 18 and 57 minutes when
administered to rats, it was appropriate to have behavioural testing follow infusion
immediately (Brusque et al., 1999). The animals are then tested for reversal o f the maze,
where they are again given the same number of training trials to learn a new location of
the hidden platform. Shultz et al (2009) showed similar perseverative behaviour measured
in the water maze, as a result o f PPA treatment. Animals persisted in returning to the
initial location of the platform and were unable to learn a new location.
\

Since PPA has been shown to have cognitive effects in the form o f perseveration of
behaviour (MacFabe et al., 2011; Shultz et al., 2009), and biochemical and
neuropathological changes have been observed following PPA infusion (MacFabe et al.,
2007; Thomas et al., 2010), it is necessary to examine the lasting effects o f PPA on
cognitive functioning over time. Chapter 2 examines the effects o f repeated, daily ICV
infusions o f PPA on the animals’ ability to acquire and subsequently reverse the maze,
either with or without the compound present. It was hypothesized, based on previous
I
studies, that the animals would have impairments in reversing the maze (i.e., learning a
new location o f the hidden platform) when under the influence o f PPA. Another purpose
of the study was to investigate the time course o f performance changes following
discontinuation o f PPA treatment. In light of the findings in Chapter 2, studies in Chapter
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3 investigated the effects o f nonspatial pretraining on the animals’ performance in the
water maze. Nonspatial pretraining is a technique designed to allow animals to acquire the
behavioural strategies that are necessary to solve the water maze (i.e., the hidden platform
is the sole refuge in the maze, the animal must swim away from the wall to find the
platform, etc.), without learning a specific spatial location of the platform. This technique
has been shown to help discriminate between the influences o f behavioural strategies
learning and the cognitive spatial learning components in the maze (Cain, 1998; Hoh &
Cain, 1999), as well as decrease the stress experienced by the animals in the maze
(Holscher, 1999). Rodents generally experience a strong stress response in the maze that
increases with experience (e.g. consecutive trials), and stress can impair performance in
this task (Cain, Boon, & Corcoran, 2006; Holscher, 1999). Not only does stress influence
cognitive functioning with regards to memory acquisition and long-term storage, but it has
also been shown to affect memory retrieval (de Quervairi, Roozendaal, & McGaugh,
1998). Thus, stress has a large impact on water maze performance, as the task is designed
to measure spatial learning and memory. Reducing the level o f this stress response is in
\
attempt to eliminate the possible confounding effects of stress on memory.
It was predicted that nonspatial pretraining would improve water maze
performance by allowing the animals to learn the necessary strategies prior to drug
administration. PPA-treated animals were expected to show persisting deficits in maze
performance, due to the diverse effects o f PPA on cognition (Brusque et al., 1999;
MacFabe et al., 2007). Previous studies have shown alterations in a variety of
physiological processes caused by PPA, such as effects on cell signaling (Nakao, Moriya,
Furuyama, Niederman, & Sugiy, 1998), neurotransmitter synthesis and release (DeCastro,
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et al., 2005), mitochondrial function (Wagner, Bayir, Ren, Puccio, Zafonte, & Kochanek,
2004), lipid metabolism (Hara, Haga, Aoyama, & Kiriyama, 1999), modulation of gene
expression (Suzuki, Nagao, Tokunaga, Katayama, & Uyeda, 1996), and gap junctional
gating (Rorig, Klausa, & Sutor, 1996). All of these physiological effects can potentially
interfere with cognitive processes that are necessary in learning in memory. Brusque and
colleagues (1999) found impaired learning in an experimental rodent model of propionic
acidemia, as measured in a shuttle-avoidance task, as well as deficits in the animals’
ability to habituate to a novel environment. Similarly, there is a robust finding of a PPAinduced innate neuroinflammatory response and phosphorylation of CREB in the model,
specifically in the hippocampal region (MacFabe et al., 2007; MacFabe et al., 2008),
which plays a large role in spatial learning and memory (O’Keefe & Nadel, 1978; Morris,
Garrud, Rawlins, & O ’Keefe, 1982). The disruption in this area, as well as the overall
effects on CNS functioning as a result of PPA treatment suggest that spatial learning
deficits should be expected. However, it has been shown that animals who have received
nonspatial pretraining prior to sustaining hippocampal damage are able to learn the maze
as well as controls (Winocur, Moscovitch, Fogel, Rosenbaum, & Sekeres, 2005). This
suggests that a detailed analysis of water maze performance following pretraining is a
valuable way to learn more about the effects of ICV PPA in the rodent model o f autism.
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Chapter 2:

Examining the Time-Course of Propionic Acid-Induced Performance Deficits in
the Morris Water Maze
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2.1 Introduction

Autism spectrum disorders are a family of lifelong disorders characterized by
communication deficits, social impairments, and restricted and/or ritualistic behaviours
(Arndt, Stodgell, & Rodier, 2005; DiCicco-Bloom et al., 2006). A subset o f patients also
present with co-morbidities, such as gastrointestinal disturbances and seizure disorder
(Besag, 2004; Horvath, Papadimitrou, Rabsztyn, Drachenberg, & Tildon, 1999).
Additionally, human autopsy studies of patients with autism have reported central nervous
system (CNS) immune activation in the form of increases in reactive astrogliosis and
activated microglia (Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005).
There have been large increases in the number of children being diagnosed with
ASD. Currently, approximately 1 in every 110 children is given a diagnosis of ASD,
which is a substantial increase from previous years (Centers for Disease Control &
\

Prevention, 2009). Research has shown that these increases are likely not completely due
to improved diagnostic criteria or increased awareness of the disorder alone (Newschaffer,
Faib, & Gurney, 2005; Rutter, 2005; King & Bearman, 2009).
Research has shown that there is a strong genetic contribution to ASD. However,
lack o f complete concordance rates amongst monozygotic twins, along with notable
variation in severity o f the disorder, even when both twins are affected, suggest that
¡genetics are not solely responsible for the disorder (Hu, Frank, Lee, & Quackenbush,
j
2006). Many environmental factors have been implicated in this disorder, which is now
widely considered to be a condition involving immune, digestive, and metabolic
dysfunction, all o f which can be triggered by these environmental factors in genetically
susceptible individuals (Ashwood & Van de Water, 2004; Chauhan & Chauhan, 2006;
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Herbert et al., 2006; Horvath & Perman, 2002). Several o f these putative environmental i;contributors have been studied, including pre- and postnatal exposure to valproic acid
(Ingram, Peckham, Tisdale, & Rodier, 2000), ethanol (Arndt, Stodgell, & Rodier, 2005),
and thalidomide (Narita, Kato, Tazoe, Miyazaki, Narita, & Okado, 2002). Similarly,
exposure to certain metals and viral infections has been implicated (Curtis, Hood, Chen,
Cobb, & Wallace; 2010; Fatemi, Cuadra, El Fakahany, Sidwell, & Thuras, 2000;
Patterson, 2009). Beyond these studies, support for an environmental hypothesis also
comes in the form o f anecdotal reports o f the worsening o f autistic symptoms following
gastrointestinal abnormalities (Horvath et al., 1999) and/or treatment with antibiotics
(Finegold, Song, & Liu, 2002; Fallon, 2005). Similarly, ingestion o f certain wheat or
dairy products has also been shown to exacerbate symptoms. A subset o f autistic patients
has shown improvements in the occurrence and severity o f symptoms once these dietary
components have been removed from their diet (Jyonouchi, Sun, & Itokazu, 2002).

i
Finally, Herbert and colleagues (2006) reported the involvement o f several
environmentally responsive genes found in linkage regions that had previously been
implicated in ASD.

'

There are many comorbidities that accompany the characteristic behavioural features
of autism. Several o f these, including epilepsy, sleep disturbances, and anxiety disorders
(Herbert et al., 2006), involve the central nervous system. Some comorbidities, such as
recurrent infection and gastrointestinal and immune difficulties involve other systems,
suggesting multisystem involvement in the disorder (Herbert et al., 2006).
Substantial intra-individual variability has been noted in autistic individuals, both in
the nature and severity o f the featured symptoms. This variability can occur in the short,

.
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medium, or long term, and may point to a metabolic and/or environmental factor, which is
labile in nature (Herbert et al., 2006). Although it is common for a child’s autistic
symptoms to wane over time, either in a spontaneous manner or in response to treatment,
these improvements have been poorly studied until very recently (Dawson & Zanolli,
2003; Fein et al., 2005; Mundy & Crowson, 1997). This response to treatment and
subsequent improvement implicates the action o f environmentally responsive disease
mechanisms - the same mechanisms that could be involved in the worsening o f symptoms
as well. Herbert and her colleagues (2006) conducted a bioinformatic analysis o f a set of
environmentally responsive genes from three relevant genomic databases, all of which
overlapped with autism linkage regions previously established in autistic patients; The
genes studied were those involved with many different functions, including cell signaling,
homeostasis, metabolism, immune/inflammatory response, and oxidative
\

stress/metabolism (Herbert et al., 2006). From this, it was concluded that autism should
be viewed etiologically as a systemic disorder that is influenced by both genetics and
.
: v. .
■ •
environmental factors.
Based on the whole-body nature of ASD, as well as the putative involvement of a
variety of different environmental factors, it was necessary to develop a model to study the
processes and mechanisms involved in the disorder. Recently, the administration of
propionic acid (PPA), as well as other short-chain fatty acids (SCFAs) has been proposed
as a novel model for ASD in the rat (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe
et al., 2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). PPA is a shortchain fatty acid that is an important metabolic fermentation product o f enteric gut bacteria
(i.e. Clostridia, Desulfovibrio, and propionibacteria) (Finegold et al., 2002; Finegold et
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al., 2010). PPA is also included in many refined wheat and dairy products as a
preservative (Brock & Buckel, 2004). Being a weak organic acid, PPA exists in both
water-soluble and lipophilic forms in the body and can readily cross lipid bilayers (such as
the gut-blood and blood-brain barriers), gaining entry into systemic and/or CNS
environments. This can occur either actively, via monocarboxylate transporters, or
passively, through diffusion (Niederman, Zhang, & Kashket, 1997; Maurer, Canis,
Kuschinsky, & Duelli, 2004).
PPA and other enteric SCFAs have been proposed as potential links between the
disparate behavioural, gut, metabolic, and immune factors implicated in autism. PPA is
known to have many physiological effects, acting on processes such as cell signaling
(Nakao, Moriya, Furuyama, Niederman, & Sugiy, 1998), neurotransmitter synthesis and
release (DeCastro, et al., 2005), immune function (Le Poul et al., 2003), modulation of
\

gene expression (Suzuki, Nagao, Tokunaga, Katayama, & Uyeda, 1996), mitochondrial
function (Wagner, Bayir, Ren, Puccio, Zafonte, & Kochanek, 2004), lipid metabolism
(Hara, Haga, Aoyama, & Kiriyama, 1999), and gating o f gap junctions (Rorig, Klausa, &
\
Sutor, 1996), all o f which have been implicated in ASD (MacFabe et al., 2007). Beyond
this wide array o f physiological effects of PPA, further evidence for the role of SCFAs in
the pathogenesis o f autism comes from the increased prevalence o f PPA-producing
bacterial species in the intestinal tracts o f autistic patients compared to healthy controls
(Finegold et al., 2002). Finally, altered PPA metabolism is present in many disorders,
such as organic acidemias, camitine/B12/biotin deficiency, and exposure to valproate or
ethanol (pre- or postnatally), all of which present with ASD-like characteristics such as
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developmental delay, GI difficulties, and seizure disorder (Coulter, 1991; Calabrese &
Rizza, 1999; Wajner, Latini, Wyse, & Dutra-Filho, 2004).
Findings using the PPA rodent model o f autism have included behavioural,
neuropathological, biochemical, and electrophysiological characteristics, all of which are
consistent with those seen in ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe et al., 2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). Behaviourally,
traits such as bouts o f hyperactivity, social impairments, perseveration, and object
preference have been observed. Electrophysiological findings have shown both caudate
spiking and limbic kindled seizures (MacFabe et al., 2007). Upon examination of
neuropathological data obtained using this model, a clear innate neuroinflammatory
response, as well as an increase in oxidative stress markers and a reduction in glutathione,
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were seen in the brains o f these rats (MacFabe et al., 2007; MacFabe et al., 2008), which
\

have also been noted in autopsy data from human patients with ASD (Chauhan &
Chauhan, 2006; Vargas et al., 2005).
In 2009, Shultz and colleagues investigated the effects of brief
\
intracerebroventricular (ICV) infusions of PPA on the cognitive and sensorimotor
functioning o f Long-Evans rats, using the Morris water maze. Animals were given either
three or five ICV infusions and then tested in the water maze for acquisition, and then
again a week later in a maze reversal task. What was found was a highly unusual pattern
of water maze performance, wherein rats treated with PPA were able to learn the maze
during acquisition just as well as controls, but were unable to learn the maze reversal task
(i.e., learn a new location o f the hidden platform) due to perseveration in returning to the
original quadrant where the platform was initially located (Shultz et al., 2009). This
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perseverative pattern o f activity is consistent with the ritualistic and repetitive behaviours
seen in autism (Sasson, Turner-Brown, Holtzclaw, Lam, & Bodfish, 2008). This finding
was corroborated by the fact that MacFabe and colleagues (2007) found increased
immunoreactivity o f the activated form of cyclic AMP responsive binding protein (CREB)
in the tissue o f the hippocampus and adjacent white matter. CREB and pCREB (the
phosphorylated and activated form) are involved in the alterations o f gene expression that
are thought to be important in learning and memory (Carlezon, Duman, & Nestler, 2005;
Silva, Kogan, Frankland, Kida, 1998). The current study further investigated this
phenomenon o f perseveratory behaviour in the PPA rodent model.
There has been evidence o f improvement in autistic symptoms following certain
treatments, some o f which involve eradication o f ASD-associated bacteria, often through
treatment with antibiotics, which decrease populations o f PPA-producing bacteria
\
(Finegold et al., 2002). Based on this, it was important to explore the long-term effects of
PPA on cognition using the rodent model. Shultz et al. (2009) found that animals treated
with single infusions o f PPA had no difficulty acquiring the maze but could not, when
given another infusion o f PPA before reversal training, learn a new location o f the hidden
platform. Thus, it was important to investigate the effects o f previous PPA loading after a
brief recovery period, where no PPA was administered, on the animals’ ability to succeed
in water maze training.
A 7-day infusion schedule, with two infusions per day, was used in the current
study, in order to be consistent with the previous work done using the PPA rodent model
i
o f autism (MacFabe et al., 2008). The present study thus differed from the previous study
(
by Shultz et al. (2009), where animals were given either three or five infusions over the
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course o f the experiment. The 7-day infusion schedule allowed data from the present
studies to be compared to previous neuropathological and biochemical findings in this
model (Thomas et al., 2010). In the present study, animals were allowed a 7-day period of
recovery (where no infusions were administered) following the 7-day infusion schedule. It
was hypothesized that while certain aspects of behaviour and cognition would persist even
after PP A treatment had been stopped, many of the behavioural effects caused by PPA
administration would return to baseline after a brief period o f recovery.

2.2 Methods
2.2.1 Subjects
Subjects were 41 adult male Long-Evans hooded rats obtained from Charles River
Laboratories (Quebec, Canada) and weighed between 200 and 250 g. Rats were housed in
\

pairs in standard acrylic cages (26 cm x 48 cm x 21 cm) in a temperature controlled colony
room (21 + 1.0 °C), and were naive to all experimental procedures. After surgery, rats
were housed individually and allowed to recover for 7-14 days, with no treatment taking
place during this time. The light/dark schedule was a 12:12 cycle with lights on at 07:00 h
and animals were allowed access to food (Prolab rat chow) and water ad libitum. All test
procedures and experimentation were carried out in accordance with guidelines of the
Canadian Council on Animal Care (CCAC) and approved by the University o f Western
Ontario Animal Use Committee.
2.2.2 Surgery: Cannula Implantation
Animals were implanted with a 23 gauge intraventricular guide cannula using
standard stereotaxic techniques. Rats were anaesthetized using inhaled 5% isoflurane and
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2 L/min oxygen flow. While in the stereotaxic device, rats were equipped with a gas
anaesthesia nose cover to maintain anaesthetic throughout surgery with 3% isoflurane and
500 mL/min oxygen flow. Under aseptic conditions, rats were implanted with a guide .
cannula in the right lateral ventricle, with the tip o f the guide cannula at the following
coordinates with reference to Bregma: anterior/posterior -1.4 mm; medial/lateral 1.8 mm;
dorsal/ventral -3.0 mm (Paxinos & Watson, 1986). Four small, stainless steel screws were
inserted into the skull surrounding the cannula to provide anchors for dental acrylic, which
attached the cannula to the skulk The cannula was sealed with a removable plug until the
time of infusion. Immediately post-surgery, all rats received a subcutaneous injection of
Ketoprofin (l mL/kg) as an analgesic.
2.2.3 Treatment Groups:
Rats were intracerebroventricularly infused with either phosphate buffered saline
(PBS; 4 uL o f 0.1 M solution) or propionic acid (PPA; 4 uL of 0.26 M solution).
i

Propionic acid was buffered to a physiological pH o f 7.4 using hydrochloric acid or
!
'
' ■
■
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sodium hydroxide. Treatment was divided into two phases: Phased and Phase II, to yield
4 treatment groups. The rats receiving PBS during Phase I followed by PBS during Phase
II were labeled PBS-PBS (n = 7). Rats receiving PPA during Phase I and PPA during
Phase II were labeled PPA-PPA (n = 12). Rats in the PPA-PBS group received PPA
during Phase I and PBS during Phase II (n = 13), and vice versa for rats in the PBS-PPA
group (n = 9). During Phased, animals received two infusions o f their assigned substance
per day, at 09:00 h and 13:00 h, for seven days. For one week after these 14 infusions, the
rats were allowed a period o f rest, where no treatment took place.
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On the day following the rest period, Phase II, rats were given two more infusions of
either the same compound that they received during Phase ! (PBS-PBS and PPA-PPA
groups), or o f the compound they did not receive during Phase I (PPA-PBS and PBS-PPA
groups). Doses were chosen based on previous dose-response findings from earlier
studies done in our lab (MacFabe et al., 2007; Shultz et al., 2008).
2.2.4 IC V Infusions
Each rat received infusions o f its assigned compound directly into the right lateral
ventricle via a 30-gauge injection cannula connected to a Sage syringe pump by PE10
tubing. The tip o f the injection cannula protruded 0.5 mm beyond the tip o f the guide
cannula. Each infusion consisted o f 4 uL o f solution delivered over a period of 1 min. To
ensure that the entire infusion had been delivered, the injection cannula was allowed to
remain in place for an additional minute before being removed. On behavioural testing
\

days, infusions were given approximately 3-5 minutes prior to the test session.
2.2.5 Behavioural Test Apparatus
2.2.5.1

Open Field Apparatus. Locomotor activity was monitored in an

EthoVisioh circular open-field arena (90 cm diameter, 40 cm high) with Beta Chip
bedding covering the floor o f the arena. A CD camera and a darkroom lamp were
mounted above the centre o f the arena. The camera was connected to a computer,
allowing behaviour to be recorded using the EthoVision 3.0.15 Behavioral Monitoring and
Analysis System at a rate o f 5.994 frames/s. This program is capable o f tracking the x-y
coordinates o f each animal and it allows for the computation o f several quantitative
variables. The camera was also connected to a VCR, allowing behaviour to be recorded
onto VIIS for later analysis.
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2.2.5.2

Water Maze. Spatial cognition was assessed using a water maze consisting

of a circular pool (1.5 m in diameter, 45 cm deep) filled with tap water at 29 ± 1.0 °C.
Hidden approximately 2 cm below the water surface was an escape platform (9 cm x 9
cm). The platform was located in the centre o f the south-east quadrant during acquisition
(Phase I), and in the centre o f the north-west quadrant during reversal (Phase II).
Polypropylene pellets floating on top of the water prevented the rats from seeing the
hidden platform by making the surface opaque (Cain, Hargreaves, Boon, & Dennison,
1993). Pictures and objects around the room provided a variety o f distal cues. Behaviour
was recorded by a video camera mounted to the ceiling above the pool. The camera was
connected to a computer and behaviour was objectively analyzed by an automated
tracking system that digitized each swim trial (Poly-Track; San Diego Instruments, San
Diego, CA).
\

2.2.6 Experimental Procedure
2. 2.6.1 Phase I. During Phase I, rats received infusions o f their assigned drug twice
a day for 7 days. On the final day o f infusions, day 7, the rats were tested in the open field
v
apparatus in the morning, following their first infusion. Each rat was placed individually
into the open field and behavioural data were collected for 30 minutes. In the afternoon,
following the second infusion o f the day, rats were tested in the water maze. Behavioural
testing commenced within approximately 3-5 minutes of the infusion.
Rats were given 10 training trials in the water maze. Each trial began with the rat
being placed in the pool, adjacent to, and facing, the pool wall at one of 4 quasi-random
start locations (north, east, south, or west), and ended when the rat stood on the hidden
platform. The platform was located in the centre o f the south-east quadrant during maze

t
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acquisition. Rats that failed to reach the hidden platform within 60 s o f the
commencement o f the trial were guided to the platform by the experimenter. Rats
remained on the platform for 15s before they were placed in a drying chamber that was
heated from above by an infrared lamp. Due to metabolic clearance rates o f the injected
substances (approximately 30 min; Brusque et al., 1999) rats were run in squads of 4 so
that the inter-trial interval for the 10 acquisition trials was not more than 5 min. For
graphic presentation o f water maze variables, the time to reach the platform was averaged
for every block o f two trials (e.g. Block 1 = (Trial 1 + Trial 2)12). Following acquisition
training in the water maze, rats were given no treatment for one week.
2. 2.6.2 Phase II: Reversal Training. Phase II consisted o f one day of infusions (at
v

09:00 h and 13 :00 h) and testing and occurred one week after the conclusion of Phase I.
Rats again received two infusions o f either PBS or PPA, with half o f the rats receiving the
\
.
infusion type (PBS or PPA) that they had not received during Phase I (i.e., PPA-PBS and
PBS-PPA groups). Following the morning infusion, rats were once again placed in the
open field apparatus for 30 minutes and behavioural data were collected.
After the afternoon infusion, the rats were again tested in the water maze, following
the same procedure as on the 7th day o f Phase I. However, the platform was now located
in the north-west quadrant o f the pool rather than the south-east quadrant, where it was
located during maze acquisition.
^

l

2.2.7 Statistical Analysis o f Behaviours
All statistical tests were calculated using SPSS 18.0 (SPSS, Inc.) for Windows.
Tests were completed using a = .05 as the criterion for significant effects.
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2. 2.7.1 Water Maze Search Latencies, Total Distance Traveled, Time Spent in
Periphery, Swim Speed, Number o f Direct and Circle Swims, and Percent First Choices to
Initial Quadrant. Search latency was defined as the time in seconds from release until the
rat climbed onto the hidden platform. Time spent in the periphery was calculated with the
periphery being defined as the outer 33% of the pool. A direct swim was defined as a
swim that remained entirely within an 18 cm wide virtual alley from the start point to the
hidden platform without crossing over itself. A circle swim was defined as a swim that
approximated an arc o f a circle without exceeding 360 degrees or crossing over itself.
Direct and circle swims are indicative of spatial place learning and were summed for each
test session.

:

Data were analyzed using a mixed design analysis o f variance (ANOVA) with
drug treatment (PBS or PPA) as the between-subjects factor and trial (10 training trials)
'
\
and test day (one or two) as the within-subjects factor. Student-Newman-Keuls (S-N-K)
post-hoc tests were carried out to obtain group differences on individual trials. ■
■'■"2.2.7.2 Open Field Total Distance Traveled, Average Speed, and Time Spent in
Periphery. Data were analyzed for main effects using a mixed design ANOVA with drug
treatment (PBS or PPA) as the between-subjects factor and time bin (six 5-min time bins)
and test day (one or two) as the within-subjects factor.
2.2.8 Monitoring o f Convulsive Activity
Rats were closely monitored for possible convulsive behaviour. Past studies from
our lab have found a kindling effect associated with repeated daily ICV infusions of PPA
in some rats (MacFabe etal., 2007). The onset of seizures may be an issue in studies
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investigating cognition or sensorimotor ability if a seizure were to occur prior to, or during
testing.
2.3 Results
2.3.1 Baseline Locomotor Activity
There were no significant group differences among the drug groups for any of the
variables measured prior to drug treatment.
2.3 2 Open Field
2.3.2.1 Total Distance Traveled. In the open field apparatus, all rats traveled
significantly less across time, F(5,195) = 25.405, p < .001. The PPA-treated group
exhibited significantly greater distances traveled than PBS controls, F( 1, 39) = 19.716, p <
.001, as seen in Fig. 2.1a. There was no significant interaction between time and drug,
F (5 ,195) = 2.034, p = .328.
\
On reversal day, all rats once again traveled significantly less across time in the open
field, F(5, 185) = 13.863,/? < .001. There was no significant main effect of drug,
however, F(3, 37) = 1.283,/? = .295 (Fig. 2.1b).
2.3.2.2 Average Speed. All rats tended to travel at a higher speed in the beginning of
the session compared to the end, F{5,195) = 103.720,/? < .001 (Fig. 2.2a). The PPAtreated group exhibited significantly greater average speeds than PBS controls across all
time bins, F{1, 39) = 19.433,/? < .001. There was no significant interaction between time
I
and drug, F(5,195) = 1.666,/? = .171.
On reversal day, all rats once again traveled at significantly lower average speeds
'1

s

across time in the open field, F(5, 185) = 83.483,/? < .001 (Fig. 2.2b). There was no
significant main effect o f drug, however, with all groups traveling at similar speeds,
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Figure 2.1 Total distance (cm) traveled in open field on Acquisition day (A) and total
distance traveled on Reversal day (B) for rats injected (ICV) with either PBS
(vehicle) or PPA (0.26M). Each point represents group mean data for each time bin
in the 30 minute session immediately following injection. Error bars represent +
SEM. PPA-treated animals traveled significantly greater distance on Acquisition
day, but there were no significant group differences found on Reversal day.
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Figure 2.2 Average speed (cm/s) in the open field apparatus on Acquisition day (A)
and average speed on Reversal day (B) for rats injected (ICV) with either PBS
(vehicle) or PPA (0.26M). Each point represents group mean data for each time bin
in the 30 minute session immediately following injection. Error bars represent +
SEM. PPA-treated rats exhibited significantly greater average speed than PBS
controls on Acquisition day. There were no significant group differences on
Reversal day.
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regardless o f drug treatment, F{3, 37) = .862, p = .469.
2.3.2.3

Time Spent in Periphery. In the open field apparatus, all rats spent less time

in the periphery o f the arena across time, F(5, 185) = 11.891 ,P < .001. However, there
was no significant main effect o f drug, F(1, 37) = 2.668, p = . 111. There was also no
significant interaction between time and drug, F(5,185) = 1.161 ,p = .328 (Fig. 2.3a).
On reversal day, all rats once again spent significantly less time in the periphery of
the open field over the course o f the testing session, F(5, 185) = 19.756,/? < .001 (Fig.
2.3b). There was no significant main effect o f drug, F(3, 37) = .352, p = .788.
2.3.3 Water Maze

f :

'

r .

2.3.3.1 Removal o f Data from Convulsive Rats. Throughout the experiment, several
rats experienced convulsive activity during acquisition o f the water maze, which occurred
immediately following infusion. This is a common feature o f rats subjected to this
\

particular infusion schedule. Because o f the nature of the task, the data collected from
these rats was excluded from water maze analyses. In total, water maze data from 16 rats
was excluded.
2.3.3.2 Search Latencies. During acquisition training, all treatment groups exhibited
decreased search times as training progressed. Significant main effects were found for
both trial, F(9,207) = 11.421,/? < .001, and drug treatment FT(1,23) = 14.755,p < .01.
j
There was also found to be a significant interaction between trial and treatment, F (9 ,207)
= 3.536, p < .01, indicating that PPA-treated rats exhibited longer search latencies on
blocks 2, 3 ,4 , and 5 (Fig. 2.4a).
On reversal Day, as shown in Fig. 2.4b, all treatment groups exhibited decreased
search times as training progressed, F(9, 189) = 8.084, p < .001. However, there were no
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Figure 2.3 Time (s) spent in the periphery of the open field on Acquisition day (A)
and on Reversal day (B) for rats injected (ICV) with either PBS (vehicle) or PPA
(0.26M). Each point represents group mean data for each time bin in the 30 minute
session immediately following injection. Error bars represent + SEM. There were
no differences on either test day in the amount of time spent in the periphery of the
open field.
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Figure 2.4 Search latencies (s) to find the hidden platform on Acquisition day (A)
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M).
Each point represents group mean data for each of 10 trials immediately following
injection. Error bars represent + SEM. * p < .05. Search latencies of PPA-treated
rats improved less across the 10 trials than controls on Acquisition day, and there
was also found to be a significant interaction between trial and drug treatment, with
search latencies of PPA rats being significantly higher than those of PBS rats on
trial blocks 2 through 5. On reversal day, there were no significant group
differences in search latencies.

\
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significant differences found among groups on reversal day F(3, 21) = 2.421, p = .061.
There was also found to be no significant interaction between trial and treatment, F(27,
189) = .703, p = .686, indicating that the improvement across trials was similar across
drug groups.
2.3.3.3 Total Distance Traveled. During acquisition training, all treatment groups
exhibited decreased distances traveled as training progressed, as seen in Fig 2.5a.
However, distances traveled by PPA-treated rats decreased less than the PBS controls.
These impressions were confirmed by ANOVA, with significant main effects being found
for both trial, F(9, 189)= 10.143, p < .001, and drug treatment F (\, 21) = 19.212, /?<
.001. There was also found to be a significant interaction between trial and drug
treatment, F (9 ,189) = 3.971,/? < .01, indicating that the decrease in total distance traveled
across trials was greater in the PBS group than in the PPA group. PPA-treated rats
\

continued to travel larger distances compared to controls on trial blocks 2 through 5.
On reversal Day, as shown in Fig 2.5b, all treatment groups exhibited decreased
distances traveled across trials, F(9, 189) = 6.239,/? < .001. However, groups receiving
'
\
'
PPA on reversal day continued to travel larger distances than controls, F (3 ,21) = 4.230,/?
< .05. There was no significant interaction between trial and drug treatment, F(27,189) =
.800,/? = .276, indicating that the improvement across trials was similar across drug
groups.
•i
2.3.3.4 Time Spent in the Periphery o f the Pool. During acquisition training, all
treatment groups exhibited decreased time spent in the periphery o f the pool as training
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Figure 2.5 Total distance (cm) traveled in the water maze on Acquisition day (A)
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M)
Each point represents group mean data for each of 10 trials immediately following
injection. Error bars represent + SEM. * p < .05. PPA-treated rats traveled
significantly greater distances on Acquisition day. There was a significant
interaction between trial and drug treatment, with PPA-treated rats continuing to
travel significantly larger distances across trial blocks 2 through 5 than PBS rats.
On Reversal day, there was a main effect of drug treatment.

\
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J

progressed (Fig 2.6a). However, PPA-treated rats continued to spend more time in the
periphery than the PBS controls. These impressions were confirmed by ANOVA, with
significant main effects being found for both trial, F(9,189) = 13.793,/? < .001, and drug
treatment F (l, 21) = 10.664,/? < .01. There was also a significant interaction between
trial and drug treatment, F(9,189) = 3.949, p < .01, indicating that the decrease in time
spent in the periphery o f the pool across trials was less for the PPA-treated rats than for
controls. PPA rats continued to spend more time in the periphery over trial blocks 2, 3,4,
and 5.
On reversal Day, as seen in Fig 2.6b, all treatment groups exhibited decreased time
spent in the periphery o f the pool across trials, F(9,189) = 7.916,

< .001. There was

also a significant main effect o f drug F (3 ,21) = 4.075,/? < .05. There was found to be no
significant interaction between trial and treatment, F(27,189) = .884, p - .340, indicating
that the improvement across trials was similar across drug groups.

,

• :
V
’
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2.3.3.6 Number o f Direct and Circle Swims. As shown in Fig. 2.7a, during
acquisition training the PPA-treated group exhibited fewer direct and circle swim paths
\
than PBS controls. ANOVA confirmed this impression, revealing a significant treatment
■
(
effect, F{1, 21) = 12.588, p < .01, with the PPA group displaying fewer direct and circle
swims than PBS controls.
As shown in Fig 2.7b, during reversal training there was no significant main effect
of treatment, F ( 3 ,18) = 3.028,/? = .056.
2.4 Discussion
This study examined the lasting cognitive effects o f ICV PPA loading, after a
one-week recovery period. It was found that treatment with PPA twice a day for seven
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Figure 2.6 Time spent in the periphery (s) of the water maze on Acquisition day (A)
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M).
Each point represents group mean data for each of 10 trials immediately following
injection. Error bars represent + SEM. * p < .05. The periphery represents the
outer third of the pool. On Acquisition day, PPA-treated rats spent more time in the
periphery than controls on trial blocks 2, 3, 4, and 5. On Reversal day, there was a
significant main effect of drug.
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Figure 2.7 Number of direct and circle swims on Acquisition day (A) and on
Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). Each
bar represents group mean data immediately following injection. Error bars
represent + SEM. * p < .05. Rats treated with PPA exhibited significantly fewer
direct and circle swims than controls. On reversal day, there were no significant
group differences in the number of direct and circle swims.
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consecutive days caused impairments in water maze acquisition. This was observed
through longer search latencies, increases in travel distances, and fewer direct and circle
swims.
2.4.1 Water Maze
The variables analyzed in the water maze were search latency, total distance
traveled, time spent in the periphery, swim speed, number o f direct and circle swims, and
percent first choices to initial quadrant. On both test days, it was observed that animals
were able to learn the water maze, with performance on all variables improving across
trials. However, animals given PPA improved less across trials than did controls.
Significant group differences were seen on all variables except for swim speed on
acquisition and reversal days (data not shown), and percent first choices to initial quadrant
during reversal (F(3, 18) = .376, ns). The lack of a significant group difference in swim
\
speed suggests that there were no major motor impairments experienced by the PPAtreated rats: The finding that PPA-treated rats exhibited the same percentage of first
choices to the initial platform-containing quadrant on reversal day suggests that PPAtreated rats in the present study did not show perseverative behaviour as was found in the
study by Shultz et al. (2009), where animals received single, spaced infusions of the
compound. This could be due to the fact that animals given PPA during Phase I were
impaired in acquiring the maze to begin with, and thus had no initial memory o f the
location o f the platform on which to perseverate.
Rats who received PPA for seven days prior to water maze acquisition were
impaired in the maze. They were unable to learn the maze as well as controls, and this
was seen in increased search latencies, larger total travel distances, more time spent in the
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periphery of the pool, and fewer direct and circle swims. All o f these findings point
towards impairments in the learning of adaptive behavioural strategies in the maze. This
finding is inconsistent with what was observed by Shultz et al. (2009), where animals
administered PPA showed a pattern of learning that was statistically no different than
controls during water maze acquisition. Shultz and colleagues (2009) found that PPAtreated rats displayed a pattern o f water maze activity that was the opposite of what is
typically seen. Rats were not impaired in acquiring the maze, but showed a marked
impairment during maze reversal. This difference in findings is likely explained by the
difference in methods between the present study and the study by Shultz et al (2009). In ;
j

the previous study, rats were given either three or five single (i.e., one infusion per day)
ICV infusions o f PPA over the course of a week prior to water maze training. In the
present study, rats were tested for maze acquisition following 14 infusions o f PPA
\

■

administered over seven consecutive days. It has been shown that infusions of PPA can
have cumulative effects in rodents! MacFabe et al. (2007) found that five consecutive days
of single PPA infusions lead to a progressive increase in the maximum level of convulsive
'
v
stage measured, as well as an increased response to a pentylenetetrazol (PTZ) treatment,
which lead to the conclusion that repeated, spaced infusions o f PPA have a kindling effect
in rodents. Similarly, occurrences o f abnormal behaviours such as limb dystonia and
hyperactivity have been shown to increase in frequency, as well as an increase in
neuroinflammation, with number o f spaced infusions (MacFabe et al., 2007; MacFabe et
al., 2008). Based on this, it is likely that PPA loading has a number o f cumulative effects,
both physiologically and cognitively, that need to be explored further.
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. Shultz et al. (2009) concluded based on their findings that rats given either three or
five single infusions o f PPA showed perseveration of behaviour in the water maze, which
was consistent with what is seen in the human disorder (Sasson et al., 2008), as well as
further findings from our lab (MacFabe et al., 2011). The marked impairment observed in
these rats during reversal training, accompanied by the increased percentage of first
choices to the quadrant where the platform was initially located during acquisition, suggest
that the animals were having difficulty unlearning the maze. This type of perseverative
behaviour was not observed in the present study, with PPA animals showing no preference
for the south-east quadrant during reversal (data not shown). Instead, what was observed
was a general deficit in water maze performance.
2.4.2 Recovery to Baseline
The purpose o f this study was to examine whether or not the observed cognitive
\

deficits caused by PPA would return to baseline after administration of the compound had
been discontinued for a substantial period o f time. Due to the fluctuating course o f ASD
symptomatology, researchers are beginning to look into the idea o f “recovery” in autism; a
concept that is not yet clearly defined. Helt and colleagues (2008) suggest that recovery
should be looked at as the loss of the behavioural characteristics o f ASD, bearing in mind
that these children are often still not identified as “normal”. To be considered
“recovered”, a term that is used conservatively in research, a child who had previously
been diagnosed with ASD must now be learning and applying new skills which are at an
appropriate age and developmental level for that child (Helt et al., 2008). For the purposes
of this study, it could be said that to be considered as “recovered”, a return to baseline
should be achieved on all variables measured, i.e., the animal is able to reverse the maze
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once drug administration has been discontinued. The findings o f the present study suggest
that recovery to baseline after previous PPA loading (i.e., two infusions per day for seven
days) appears possible, based on the behaviours tested in the water maze and open field,
following discontinuation o f the drug for a period o f seven days. Animals who received
two final infusions o f PPA on reversal day, regardless of which drug they received during
Phase I o f the study, were impaired in reversing the maze compared to controls,
suggesting that two infusions o f PPA are enough to cause deficits in cognition. Animals
in the PPA-PBS group (i.e., the “recovery” group) showed a pattern of performance on
reversal day that was often at the same level as controls. The “recovery” group did show
an intermediate level o f performance by traveling longer distances and spending more
time in the periphery o f the pool than controls, however this finding did not reach
significance. This suggests that certain behaviours return to baseline, whereas others may
\
be more permanent. Further research should be conducted to explore whether or not these
intermediate deficits remain over a longer time period, or whether performance of
previously PPA-loaded animals can return completely to baseline if given sufficient time
to recover. Similarly, it would be beneficial to investigate the time course o f other
behaviours that are relevant to ASD (i.e., social behaviours), as well as other
neuropathological (i.e., CREB) and biochemical (i.e., phospholipid/acylcamitine) markers.
All of these studies are ongoing in our laboratory.
There are varying levels o f cognitive impairment observed in individuals with ASD.
The disorder can occur with or without cognitive impairment, with some individuals
experiencing profound deficits in IQ and others achieving normal levels (Dawson,
Soulieres, Gemsbacher, & Mottron, 2007). In fact, the reported percentages o f children
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with ASD who fall in the range defined as mental retardation are between about 25 and
64% (Kielinen, Linna, & Moilanen,' 2000). The present study models a more severe
cognitive impairment, which has been shown to be dependent on dose o f PPA in our
model (MacFabe et al., 2007). It is interesting that even though these animals experienced
extreme cognitive impairments in the water maze, they were still able to show
improvements to baseline levels following discontinuation o f PPA treatment.
(2,4.3 Convulsive Activity

,

'

'

In the present study, water maze data from 16 of the 41 animals tested was removed
due to convulsive activity that was observed during acquisition training in the water maze.
o
Many rats experience convulsive activity as a result of continued PPA infusions. The
kindling effect o f PPA has been well noted (MacFabe, 2007), and so the presence of
convulsions throughout such a rigorous infusion schedule, such as the one used in the
v
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present study, is not surprising. Although it cannot be concluded that some or all of the
convulsive activity seen following infusions was actually seizure activity without EEG data, it is a possibility. Furthermore, some seizure types (i.e., hippocampal seizures)
produced by PPA are conconvulsive and present with movement arrest or immobility
(MacFabe et al., 2007). Conversely, movement disorder has been observed in the model,
which appears as convulsive behaviour. This behaviour, however, was accompanied by
basal ganglial spiking rather than cortical spiking, which is more often characteristic of
seizure (MacFabe et al., 2007). If a seizure were to occur prior to or during testing, this
would interfere with cognition and thus the animal’s ability to acquire the maze.
Convulsive activity was also often observed as full-body clonus, which alone can make
*

C

activities such as swimming and climbing onto a platform very difficult. It was for this
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reason that data from rats that displayed convulsive activity was removed entirely from all
water maze analyses. This, however, leads to a slightly different problem, where rats that
were resistant to convulsive/seizure activity were selected for, unintentionally. It is
possible that the rats that were able to receive 14 infusions o f PPA over the course of
seven days without displaying convulsive activity have some common characteristic that
could have skewed the data presented here. Similarly, because seizure disorder is a
common comorbidity o f ASD (Besag, 2004), eliminating this data may have resulted in
the exclusion o f data that may have been informative. For the purposes o f this study,
however, the conservative choice o f leaving these data out of the behavioural analyses for
water maze was deemed more suitable. Further studies should be conducted to elucidate
the precise role that convulsive activity plays in the model.
2.4.4 Conclusions
Findings from the present study are suggestive of a return to baseline on behavioural
variables measured in the water maze arid open field apparatus following discontinuation
of PPA treatment. The cognitive deficits caused by PPA did not appear to be the result of
perseveration in the water maze, as was seen in previous work by Shultz et al. (2009).
Instead, the animals appeared to be unable to acquire or reverse the maze immediately
following PPA infusion. Interestingly, this severe cognitive impairment-returned to
baseline levels after discontinuation o f PPA treatment, indicating that the cognitive
deficits measured in the water maze resulting from PPA treatment are not permanent.
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Chapter 3:

Acid-Treated Rats With and Without a Recovery Period
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3.1 Introduction
Autism spectrum disorders (ASDs) are a cluster of neurodevelopmental disorders
that generally present with communication deficits, social impairments, motor
abnormalities, and restricted or ritualistic interests (Arndt, Stodgell, & Rodier, 2005;
DiCicco-Bloom et al., 2006). Environmental factors are being considered more widely in
autism research as potential contributors to the development and/or exacerbation of ASD
(Ashwood & Van de Water, 2004; Chauhan & Chauhan, 2006; Herbert et ah, 2006;
Horvath & Perman, 2002). The increasing prevalence of the disorder (Centers for Disease
Control & Prevention, 2009), as well as the lack of complete concordance between
monozygotic twins (Hu, Frank, Lee, & Quackenbush, 2006), have lead researchers to
investigate potential environmental agents that may contribute to the disorder. For
instance, studies have investigated the effects of pre- and postnatal exposure to valproic
acid (Ingram, Peckham, Tisdale, & Rodier, 2000), ethanol (Arndt, Stodgell, & Rodier,
2005), and thalidomide (Narita, Kato, Tazoe, Miyazaki, Narita, & Okado, 2002).
Similarly, exposure to certain metals and viral infections has been implicated as well
(Curtis, Hood, Chen, Cobb, & Wallace, 2010; Fatemi, Cuadra, El Fakahany, Sidwell, &
Thuras, 2000; Patterson, 2009). ASD is beginning to be considered as a multisystem
disorder involving immune, digestive, and metabolic dysfunction, all of which can be
triggered by these environmental factors in genetically susceptible individuals (Ashwood
& Van de Water, 2004; Chauhan & Chauhan, 2006; Herbert et ah, 2006; Horvath &
Perman, 2002).
Further support for an environmental hypothesis comes from anecdotal reports of
parents of autistic children of the worsening of autistic symptoms following
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gastrointestinal abnormalities (Horvath, Papadimitriou, Rabsztyn, Drachenberg, & Tildon,
1999) and routine or antibiotic-resistant pediatric infections (Finegold, Song, & Liu, 2002;
Fallon, 2005). Similarly, it has been reported that the worsening of symptoms can follow
the ingestion of wheat or dairy products in a subset of patients. Some patients also show
improvement in ASD symptoms following the removal of these types of foods from the
diet (Jyonouchi, Sun, & Itokazu, 2002). Based on these findings, Herbert et al. (2006)
investigated the possibility o f “environmentally responsive genes” that may be associated
with ASD symptomatology. What they found was the presence of several
environmentally responsive genes that had previously been identified in linkage regions
associated with ASD. Among the genes studied by Herbert and her colleagues (2006)
were those involved with many different functions, including cell signaling, homeostasis,
metabolism, immune/inflammatory response, and oxidative stress/metabolism. This
finding points towards autism being a whole-body, systemic disorder rather than just a
brain disorder, whose development and symptomatic presentation are influenced by both
genetics and environmental factors.
Research is beginning to show that autistic symptoms in certain individuals can wax
and wane depending on various factors such as diet or treatment with antibiotics or
antioxidants (Horvath, Papadimitriou, Rabsztyn, Drachenberg, & Tildon, 1999). In fact,
the intra-individual variability in the nature and severity of symptoms that has been
reported is substantial (Herbert et al., 2006). This response to treatment and/or potential
spontaneous improvement, which has been shown to happen in the short, medium, or long
term, points towards the action of environmentally responsive disease mechanisms. These
same mechanisms could also be involved in the observed worsening of symptoms. This
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empirical evidence of improvement and/or worsening of autistic symptoms suggests that
the idea o f “recovery” is an area that should be further explored.
Based on the implication of an environmental contribution to ASD, the propionic
acid (PPA) model of autism has been proposed (MacFabe et al., 2007; MacFabe et al.,
2008; MacFabe, Cain, Boon, Ossenkopp, & Cain, 2011; Shultz et al., 2008; Shultz et al.,
2009; Thomas, Foley, Mepham, Tichenoff, Possmayer, & MacFabe, 2010). PPA is a
short-chain fatty acid that is an important metabolic byproduct of fermentation of certain
types of bacterial species in the gut (i.e., Clostridia, Desulfovibrio, and propionibacteria)
(Finegold et al., 2002; Finegold et al., 2010). PPA is also included in many refined wheat
and dairy products as a preservative (Brock & Buckel, 2004). As a weak organic acid,
PPA exists in both water-soluble and lipophilic forms in the body and can readily cross
lipid bilayers (such as the gut-blood and blood-brain barriers), gaining entry into systemic
and/or CNS environments. This occurs both actively, via monocarboxylate transporters,
and passively, through diffusion (Niederman, Zhang, & Kashket, 1997; Maurer, Canis,
Kuschinsky, & Duelli, 2004).
PPA and other enteric SCFAs have been proposed as potential links between the
disparate behavioural, gut, metabolic, and immune factors implicated in autism. There are
many known physiological effects of PPA, including effects on cell signaling (Nakao,
Moriya, Furuyama, Niederman, & Sugiy, 1998), neurotransmitter synthesis and release
(DeCastro, et al., 2005), immune function (Le Poul et al., 2003), modulation of gene
expression (Suzuki, Nagao, Tokunaga, Katayama, & Uyeda, 1996), mitochondrial
function (Wagner, Bayir, Ren, Puccio, Zafonte, & Kochanek, 2004), lipid metabolism
(Hara, Haga, Aoyama, & Kiriyama, 1999), and gating of gap junctions (Rorig, Klausa, &
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Sutor, 1996), all o f which have been implicated in ASD (MacFabe et al., 2007). In
addition to the widespread effects o f PPA, further evidence for the involvement o f SCFAs
in autism comes from the increased prevalence of PPA-producing bacterial species in the
intestinal tracts of ASD patients compared to healthy controls (Finegold et al., 2002;
Finegold et al., 2010).
MacFabe and colleagues (2007; 2008; 2010) have found that the administration of
PPA, as well as other short-chain fatty acids (SCFAs), has been found to produce ASDlike behavioural and neuropathological effects in rodents. In 2010, Thomas et al. added to
the validity of the model by demonstrating that intracerebroventricular (ICV) infusions of
PPA caused changes in the lipid profiles in the blood and brain tissue of rats that were
consistent with the alterations in lipid profiles found in the blood of autistic patients (Bell,
Sargent, Tocher, & Dick, 2000; Clark-Taylor & Clark-Taylor, 2004). Interestingly,
though PPA is a regular byproduct of cellular metabolism and is produced by anaerobic
fermentation in the gut, it is also produced at increased levels by bacterial species such as
Clostridial species that are present in the intestinal tracts of ASD patients but not present
in controls (Finegold et al., 2002). These traits suggest that PPA and other SCFAs might
be a potential link between the behavioural, gut, metabolic, and immune factors implicated
in autism.
Studies using the PPA rodent model o f autism have produced behavioural,
neuropathological, biochemical, and electrophysiological findings that are all consistent
with what is seen in ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe et al.,
2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). Behaviourally, traits
such as bouts of hyperactivity, social impairments, perseveration, object fixation, and
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repetitive movements have been observed. Electrophysiological findings have shown both
caudate spiking associated with dystonia and limbic kindled seizures (MacFabe et al.,
2007). A clear innate neuroinflammatory response, as well as an increase in oxidative
stress markers and altered lipid profiles, were seen in the brains of these rats, which have
also been noted in autopsy data from human patients with ASD (Chauhan & Chauhan,
2006; Vargas et al., 2005).
A study by Shultz et al. (2009) presented interesting findings using the PPA rodent
model, wherein rats treated with brief intracerebroventricular infusions of PPA were able
to learn the location o f a hidden platform in the Morris water maze, but could not
subsequently learn a new location of the platform. Animals in this experiment were given
either three or five single infusions of PPA over the course o f one week. Immediately
following an infusion o f the compound, animals were tested in the maze for acquisition,
and then infused and tested one week later in a maze reversal task. Throughout reversal,
the animals continued to return to the quadrant of the maze that initially housed the hidden
platform, which is suggestive of perseverative behaviour (Shultz et al., 2009). This is
consistent with the ritualistic and repetitive behaviours seen in patients with ASD (Sasson,
Turner-Brown, Holtzclaw, Lam, & Bodfish, 2008). This finding lead to the investigation
of the lasting cognitive effects of PPA after a brief period of recovery, where no PPA was
administered.
In the previous study, Mepham et al. (2011) investigated the effects of PPA loading
on the animals’ ability to succeed at a maze reversal task (i.e., to learn a new location of
the hidden platform) when administration of the compound had been ceased for seven
days (see Chapter 2). Based on the evidence of improvement and worsening in ASD, it
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was important to study the time course of the cognitive, behavioural, and
neuropathological deficits induced by SCFAs in the PPA rodent model of autism. In the
previous study, animals were tested for reversal of the water maze, following 7 days of
PPA loading, in either the presence or absence of PPA. Results showed that not only were
PPA-treated rats unable to acquire the maze properly, but they also were unable to reverse
the maze. Ultimately, it was found that rats who received PPA on the day of maze
reversal were unable to reverse the maze, whereas rats who were given PBS on reversal
day learned the new location of the platform at the same level as controls, regardless of
whether or not they had been loaded with PPA prior to acquisition (twice a day for seven
days). Unlike the study by Shultz et al. (2009) that used only three or five single ICV
infusions of PPA, it was concluded that two infusions per day for seven days was enough
to disrupt cognitive functioning as measured in the Morris water maze. However, it was
unclear which aspect of the task was being affected, and thus the nature of the observed
impairment needed to be clarified. Water maze acquisition involves two main
components. The first component is the learning o f the behavioural strategies necessary
for solving this task (Cain & Boon, 2003). This includes learning that the hidden platform
is the only possible refuge from the pool, that attempts to climb out of the pool need to be
suppressed, and that the platform is never located near the wall. Although rats are
naturally very adept swimmers, they still experience a great deal of stress in the pool
(Beiko, Lander, Hampson, & Cain, 2004) and the advanced learning o f these behavioural
strategies acts to alleviate some of this stress. The second component of water maze
acquisition is the spatial learning component, which is generally the basis of how water
maze data is interpreted. This aspect o f the task deals with the animal’s ability to learn the
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actual spatial location of the platform from any release point, based on the visual cues
around the room (Cain & Boon, 2003). In order for the animal to successfully learn the
spatial aspect o f the maze, it must first acquire the behavioural skills necessary to
complete the maze. From an interpretation perspective, it is beneficial to differentiate
between the two components in order to understand exactly which processes are being
affected by the experimental treatment.
Given that there are two distinct components of water maze acquisition, it was
important to investigate which aspect of maze performance was being disrupted by PPA
administration. The aim of the current study, therefore, was to examine the effects of PPA
loading on maze acquisition and reversal in animals that had previously been exposed to
nonspatial pretraining in the maze, prior to drug treatment. Nonspatial pretraining is a
technique designed to teach the animals the behavioural strategies necessary for
successfully completing the maze, without having the rat learn a specific spatial location
of the platform (Cain & Boon, 2003). Allowing the animals to be trained in the maze
without learning a spatial location of the platform was expected to give a better indication
of whether PPA treatment was interfering with strategies learning or spatial learning. It
was hypothesized that nonspatial pretraining would improve the performance of PPAtreated animals in the water maze by allowing them to learn the behavioural strategies
necessary to solve the maze prior to treatment, and by reducing the stress experienced
during the task.
3.2 Methods
3.2.1 Subjects
Subjects were 26 adult male Long-Evans hooded rats obtained from Charles River
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Laboratories (Quebec, Canada) and weighed between 200 and 250 g. Rats were
housed in pairs in standard acrylic cages (26 cm x 48 cm x 21 cm) in a temperature
controlled colony room (21 + 1.0 °C), and were naive to all experimental procedures.
After surgery, rats were housed individually and allowed to recover for 7-14 days, with no
treatment taking place during this time. The light/dark schedule was a 12:12 cycle with
lights on at 07:00 h and animals were allowed access to food (Prolab rat chow) and water
ad libitum. All test procedures and experimentation were carried out in accordance with
guidelines of the Canadian Council on Animal Care (CCAC) and approved by the
University o f Western Ontario Animal Use Committee.
3.2.2 Surgery: Cannula Implantation
Animals were implanted with a 23 gauge intracerebroventricular guide cannula
using standard stereotaxic techniques. Rats were anaesthetized using inhaled 5%
isoflurane and 2 L/min oxygen flow. While in the stereotaxic device, rats were equipped
with a gas anaesthesia nose cover to maintain anaesthetic throughout surgery with 3%
isoflurane and 500 mL/min oxygen flow. Under aseptic conditions, rats were implanted
with a guide cannula in the right lateral ventricle, with the tip of the guide cannula at the
following coordinates with reference to Bregma: anterior/posterior -1.4 mm; medial/lateral
1.8 mm; dorsal/ventral -3.0 mm (Paxinos & Watson, 1986). Four small, stainless steel
screws were inserted into the skull surrounding the cannula to provide anchors for dental
acrylic, which attached the cannula to the skull. The cannula was sealed with a removable
plug until the time of infusion. Immediately post-surgery, all rats received a subcutaneous
injection of Ketoprofin (1 mL/kg) as an analgesic.
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3.2.3 Treatment Groups:
Rats were intracerebroventricularly infused with either phosphate buffered saline
(PBS; 4 uL of 0.1 M solution) or propionic acid (PPA; 4 uL of 0.26 M solution).
Propionic acid was buffered to a physiological pH of 7.4 using hydrochloric acid or
sodium hydroxide. Treatment was divided into two phases: Phase I and Phase II to yield 4
treatment groups. The rats receiving PBS during Phase I followed by PBS during Phase II
were labeled PBS-PBS (n = 6). Rats receiving PPA during Phase I and PPA during Phase
II were labeled PPA-PPA (n = 8). Rats in the PPA-PBS group received PPA during Phase
I and PBS during Phase II (n = 6), and vice versa for rats in the PBS-PPA group (n = 6).
During Phase I, animals received two infusions of their assigned substance per day, at
09:00 h and 13:00 h, for seven days. For one week after these 14 infusions, the rats were
allowed a period of rest, where no treatment took place.
On the day following the rest period, Phase II, rats were given two more infusions of
either the same compound that they received during Phase I (PBS-PBS and PPA-PPA
groups), or o f the compound they did not receive during Phase I (PPA-PBS and PBS-PPA
groups). Doses were chosen based on previous dose-response findings from earlier
studies done in our lab (MacFabe et al., 2007; Shultz et al., 2008).
3.2.4 ICVInfusions
Each rat received infusions of its assigned compound directly into the right lateral
ventricle via a 30-gauge injection cannula connected to a Sage syringe pump by PE10
tubing. The tip o f the injection cannula protruded 0.5 mm beyond the tip of the guide
cannula. Each infusion consisted of 4 uL of solution delivered over a period of 1 min. To
ensure that the entire infusion had been delivered, the injection cannula was allowed to
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remain in place for an additional minute before being removed. On behavioural testing
days, infusions were given approximately 3-5 minutes prior to the test session.
2.2.5 Behavioural Test Apparatus
2.2.5.1

Open Field Apparatus. Locomotor activity was monitored in an

EthoVision circular open-field arena (90 cm diameter, 40 cm high) with Beta Chip
bedding covering the floor of the arena. A CD camera and a darkroom lamp were
mounted above the centre o f the arena. The camera was connected to a computer,
allowing behaviour to be recorded using the EthoVision 3.0.15 Behavioral Monitoring and
Analysis System at a rate of 5.994 frames/s. This program is capable of tracking the x-y
coordinates of each animal and it allows for the computation of several quantitative
variables. The camera was also connected to a VCR, allowing behaviour to be recorded
onto VHS for later analysis.
2.2.5.2

Water Maze. Spatial cognition was assessed using a water maze consisting

of a circular pool (1.5 m in diameter, 45 cm deep) filled with tap water at 29 + 1.0 °C.
Hidden approximately 2 cm below the water surface was an escape platform (9 cm x 9
cm). The platform was located in the centre of the south-east quadrant during acquisition
(Phase I), and in the centre of the north-west quadrant during reversal (Phase II).
Polypropylene pellets floating on top of the water prevented the rats from seeing the
hidden platform by making the surface opaque (Cain, Hargreaves, Boon, & Dennison,
1993). Pictures and objects around the room provided a variety o f distal cues. Behaviour
was recorded by a video camera mounted to the ceiling above the pool. The camera was
connected to a computer and behaviour was objectively analyzed by an automated
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tracking system that digitized each swim trial {Poly-Track, San Diego Instruments, San
Diego, CA).
3.2.6 Experimental Procedure
3.2.6.1 Non-Spatial Pretraining. Pretraining was carried out one week after cannula
implantation surgery. Pretraining took place on one day, day 0, when rats were given 10
trials each with a 5 minute intertrial interval. Only one rat swam in the pool at a time. For
nonspatial pretraining, thick black curtains, attached to a circular track mounted to the
ceiling, were drawn completely around the pool, eliminating all distal cues. The visible
portion of the ceiling above the pool was uniform and provided no directional cues. The
hidden platform was moved to a new quadrant after every pretraining trial. A rat was
introduced into the pool and swam until it found the hidden platform or 120 s elapsed, at
which time it was placed on the platform where it remained for 30 s. Swimming was
observed on the television monitor, and search times were recorded. The acquisition of
water maze behavioural strategies during pretraining has been documented (Cain, Boon, &
Corcoran, 2006; Perrot-Sinal, Kosteniuk, Ossenkopp, & Kavaliers, 1996).
3.2.6.2 Phase I. During Phase I, rats received infusions of their assigned drug twice
a day for 7 days. On the final day of infusions, day 7, the rats were tested in the open field
apparatus in the morning, following their first infusion. Each rat was placed individually
into the open field and behavioural data were collected for 30 minutes. In the afternoon,
following the second infusion of the day, rats were tested in the water maze. Behavioural
testing commenced within approximately 3-5 minutes of the infusion.
Rats were given 10 training trials in the water maze. Each trial began with the rat
being placed in the pool, adjacent to, and facing, the pool wall at one of 4 quasi-random
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start locations (north, east, south, or west), and ended when the rat stood on the hidden
platform. The platform was located in the centre of the south-east quadrant during maze
acquisition. Rats that failed to reach the hidden platform within 60 s o f the
commencement of the trial were guided to the platform by the experimenter. Rats
remained on the platform for 15 s before they were placed in a drying chamber that was
heated from above by an infrared lamp. Due to metabolic clearance rates o f the injected
substances, rats were run in squads of 4 so that the inter-trial interval for the 10 acquisition
trials was not more than 5 min. For graphic presentation of water maze variables, the time
to reach the platform was averaged for every block of two trials (e.g. Block 1 = (Trial 1 +
Trial 2)12. Following acquisition training in the water maze, rats were given no treatment
for one week.
3.2.6.3

Phase II. Phase II consisted of one day of infusions (at 09:00 h and 13:00 h)

and testing and occurred one week after the conclusion of Phase I. Rats again received
two infusions o f either PBS or PPA, with half o f the rats receiving the infusion type (PBS
or PPA) that they had not received during Phase I (i.e., PPA-PBS and PBS-PPA groups).
Following the morning infusion, rats were once again placed in the open field apparatus
for 30 minutes, and behavioural data was collected.
After the afternoon infusion, the rats were again tested in the water maze, following
the same procedure as on the 7th day of Phase I. However, the platform was now located in
the north-west quadrant of the pool rather than the south-east quadrant, where it was
located during maze acquisition.
3.2.7 Statistical Analysis o f Behaviours
All statistical tests were calculated using SPSS 18.0 (SPSS, Inc.) for Windows.
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Tests were completed using a = .05 as the criterion for significant effects.
3.2.7.1 Water Maze Search Latencies, Total Distance Traveled, Time Spent in
Periphery, Swim Speed, Number o f Direct and Circle Swims, and Percent First Choices to
Initial Quadrant. Search latency was defined as the time in seconds from release until the
rat climbed onto the hidden platform. Time spent in the periphery was calculated with the
periphery being defined as the outer 33% o f the pool. A direct swim was defined as a
swim that remained entirely within an 18 cm wide virtual alley from the start point to the
hidden platform without crossing over itself. A circle swim was defined as a swim that
approximated an arc o f a circle without exceeding 360 degrees or crossing over itself.
Direct and circle swims are indicative of spatial place learning and were summed for each
test session.
Data were analyzed using a mixed design analysis of variance (ANOVA) with drug
treatment (PBS or PPA) as the between-subjects factor and trial (10 training trials) and test
day (one or two) as the within-subjects factor. Student-Newman-Keuls (S-N-K) post-hoc
tests were carried out to obtain group differences on individual trials.
3.2.7.2 Open Field Total Distance Traveled, Average Speed, and Time Spent in
Periphery. Data were analyzed for main effects using a mixed design ANOVA with drug
treatment (PBS or PPA) as the between-subjects factor and time bin (six 5-min time bins)
and test day (one or two) as the within-subjects factor.
3.2.8 Monitoring o f Convulsive Activity
Rats were closely monitored for possible convulsive behaviour. Past studies from
our lab have found a kindling effect associated with repeated daily ICV infusions of PPA
in some rats (MacFabe et al., 2007). The onset of seizures may be an issue in studies
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investigating cognition or sensorimotor ability if a seizure were to occur prior to, or during
testing.
3.2.9 Tissue Preparation and Histology
The day after the reversal test day (Phase II), rats were deeply anaesthetized with
sodium pentobarbital (270 mg/mL) and perfused transcardially with ice cold 0.1 M
phosphate buffered saline (PBS, pH 7.5) followed by 4% paraformaldehyde in PBS. The
brain was removed from the skull and placed in 4% paraformaldehyde solution to be
stored at 4 °C for 24 h. Following the fixation period, brains were placed in 18% sucrose
solution prior to paraffin embedding. Selected coronal blocks from various brain regions
(frontal cortex/striatum and dorsal hippocampus) were dehydrated and defatted by
increasing concentrations of ethanol/xylenes using standard histological procedures, and
embedded in paraffin wax for permanent storage. Serial 4 um sections were obtained
through the right lateral ventricle (cannula site) and the ipsilateral dorsal hippocampus,
including adjacent white matter o f the external capsule. The sections were then stained
using standard immunohistochemical procedures, for glial fibrillary acidic protein (GFAP;
1:500, polyclonal, DakoCytomation, Glostrup, Denmark), a marker for reactive astrocytes
in the central nervous system, and Iba-1 (1:10,000, rabbit polyclonal, Wako, Richmond,
VA), a marker for activated microglia. Tissue sections were mounted on glass slides
(SurgiPath, Canada) and dried overnight at 37°C. Sections were deparaffinized and
rehydrated using standard immunohistochemical procedures for antigen recovery (Shi,
Cote, & Taylor, 2001). Endogenous peroxidase activity was blocked using a 3% hydrogen
peroxide in distilled water solution for 5 min. For antigen recovery, sections were
immersed in boiling 0.21% citric acid buffer (pH 6.0) for 30 min in a 1250W microwave
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oven. Slides were counterstained with Gill haematoxylin (EMD Biosciences) and rinsed
with PBS for 5 min. A 10% normal horse serum in PBS solution was applied for 5 min
followed by the primary antibodies for 1 hr at room temperature. Following the incubation
period, sections were washed with PBS and secondary antibodies, either biotinylated anti
mouse IgG (Vector Laboratories, Burlingame, CA-BA2000) or biotinylated anti-rabbit
(Vector Laboratories, Burlingame CA-BA1000) for 30 min. Tissues were again washed
with PBS and stained using the avidin-biotin complex (Vectastain Elite ABC, Vector
Laboratories, Burlingame, CA- PK6100) for 30 min at room temperature. Following
incubation, slides were washed with PBS and 3, 3- diaminobenzidine DAB chromagen
(Sigma-D8001) was applied for 5 min. After final rinsing, slides were dehydrated,
cleared, and coverslipped.
Due the diffuse nature of GFAP and IbAl staining, analyses were completed by
using the ‘area stained’ function within ImagePro Plus which sums the immunopositive
area within a digital image to provide a total immunopositive area per picture (pm2).

3.3 Results
3.3.1 Baseline Locomotor Activity
There were no significant group differences among the drug groups for any of the
variables measured prior to drug treatment.
3.3.2 Open Field Apparatus
3.3.2.1

Total Distance Traveled. In the open field apparatus, all rats traveled

significantly less across time, F(5, 120) = 23.905, p < .001. There was a main effect of
drug, F{ 1, 24) = 32.320,/) < .001. There was also a significant interaction between time
and treatment, F(5, 120) = 2.924, p < .05. This indicates that PPA-treated rats traveled
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more across time and their total distances decreased less than PBS controls over the final
25 minutes in the open field (Fig. 3.1a).
On reversal day, all rats once again traveled significantly less across time in the open
field, .F(5, 110) = 17.659,/» < .001 (Fig. 3.1b). There was no significant main effect of
drug, however , F(3, 22) = .181,/» = .908.
3.3.2.2

Average Speed. In the open field apparatus, all rats tended to travel at a

higher speed in the beginning o f the session compared to the end, F(5, 120) = 76.535, p <
.001. The PPA-treated group exhibited significantly greater average speeds than PBS
controls across time, F (l, 24) = 45.959, p < .001 (Fig. 3.2a). There was also a significant
interaction between time and drug treatment, F(5, 120) = 2.769, p < .05. PPA-treated rats
traveled at higher speeds than controls over time, however, this difference decreased
across time bins.
On reversal day, as seen in Fig. 3.2b, all rats once again traveled at significantly
lower average speeds in the open field as the session progressed, F(5, 110) = 36.972, p
< .001. There was no significant main effect of drug, however, with all groups traveling at
similar speeds, regardless o f drug treatment, F{3, 22) = .239,/» = .868.
3.3.3 Water Maze
3.3.3.1

Removal o f Data from Convulsive Rats. Throughout the experiment, several

rats experienced convulsive activity during acquisition of the water maze, which occurred

78

Figure 3.1 Total distance (cm) traveled on Acquisition day (A) and total distance
traveled on Reversal day (B) for rats injected (ICV) with either PBS (vehicle) or PPA
(0.26M). Each point represents group mean data for each time bin in the 30 minute
session immediately following injection. Error bars represent + SEM. * p < .05. On
Acquisition day, PPA-treated animals traveled significantly greater distances than
controls over the last 25 minutes in the open field. There were no significant group
differences found on Reversal day.
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Figure 3.2 Average speed (cm/s) in the open field apparatus on Acquisition day (A)
and average speed on Reversal day (B) for rats injected (ICV) with either PBS
(vehicle) or PPA (0.26M). Each point represents group mean data for each time bin
in the 30 minute session immediately following injection. Error bars represent +
SEM. * p < .05. PPA-treated rats exhibited significantly greater average speeds,
and their average speeds decreased less across trials than PBS controls on
Acquisition day. There were no significant group differences on Reversal day.

81

Average Speed in Open Field on Acquisition Day

Time Bin

Average Speed in Open Field on Reversal Day

14 -i

12

-

10

-

2

-

- O - PBS-PBS (6)
—• - PPA-PPA(S)
—O - PPA-PBS (6)
PBS-PPA (6)

0
1

2

3

4

Time Bin

5

6

82

immediately following infusion. This is a common feature of rats subjected to this
particular infusion schedule. Because o f the nature o f the task, the data collected from
these rats was excluded from water maze analyses. In total, water maze data from five rats
was excluded.
33.3.2 Search Latencies on Pretraining Trials. During nonspatial pretraining in the
water maze, there was a significant effect o f pretraining trial, F(9, 216) = 7.997, p < .001,
indicating that all animals learned the strategies necessary to solve the maze. By dividing
the rats into drug groups based on the treatment they would receive following pretraining,
there were no significant group differences, F (l, 24) = .511,p = .875 (Fig. 3.3). This
suggests that groups who would receive PPA during Phase I were able to learn the
strategies of the maze just as well as control rats.
3.3.33 Search Latencies. During acquisition training, both treatment groups
exhibited decreased search times as training progressed. However, performance of the
PPA-treated rats improved less than the PBS controls. These impressions were confirmed
by ANOVA, with significant main effects being found for both trial, F(9, 171) = 9.129, p
< .001, and drug treatment F (l, 19) = 15.596 , p < .01. There was found to be no
significant interaction between trial and treatment, F(9, 171) = .992, p = .423 (Fig. 3.4a).
On reversal Day, as shown in Fig. 3.4b, all treatment groups exhibited decreased
search times as training progressed, F(9, 153) = 6.961 >P< .001. There was a significant
main effect o f drug treatment, F(3, 17) = 5.985,p < .01. There was found to be no
significant interaction between trial and treatment, F(27, 153) = 1.533, p = .129, indicating
that the improvement across trials was similar across drug groups.
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Figure 3.3 Search latencies (s) during pretraining trials for untreated rats. Each
point represents group mean data for each of 10 pretraining trials. Error bars
represent + SEM. Search latencies of all rats decreased across pretraining trials,
with no group differences between rats who were subsequently given PPA and
those who were subsequently given PBS.
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Figure 3.4 Search latencies (s) to find the hidden platform on Acquisition day (A)
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M).
Each point represents group mean data for each of 10 trials immediately following
injection. Error bars represent + SEM. There was a significant main effect of drug
treatment on Acquisition day. On reversal day, there was again a significant main
effect of drug.
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3.3.3.4 Total Distance Traveled. During acquisition training, all treatment groups
exhibited decreased distances traveled as training progressed. However, distances traveled
by PPA-treated rats decreased less overall than the PBS controls. These impressions were
confirmed by ANOVA, with significant main effects being found for both trial, F{9, 171)
= 6.183 ,/? < .001, and treatment F (l, 19) = 16.876,/? < .01. There was found to be no
significant interaction between trial and treatment, F(9, 171) = 1.225,/? = .305 (Fig. 3.5a).
On reversal Day, as shown in Fig. 3.5b, all treatment groups exhibited decreased
distances traveled across trials, F(9, 153) = 4.816,/? < .01. However, groups receiving
PPA on reversal day continued to travel larger distances than animals given PBS, F (l, 17)
= 6.294,/? < .01. There was found to be no significant interaction between trial and
treatment, F(27, 153) = 11.674,/? = .088, indicating that the improvement across trials was
similar across drug groups.
3.3.3.5 Time Spent in the Periphery. During acquisition training, all treatment
groups exhibited decreased time spent in the periphery of the pool as training progressed.
However, PPA-treated rats continued to spend more time in the periphery than the PBS
controls, as seen in Fig. 3.6a. These impressions were confirmed by ANOVA, with
significant main effects being found for both trial, F(9, 171) = 8.110,/? < .001, and drug
treatment F( 1, 19) = 8.399,/? < .01. There was found to be no significant interaction
between trial and treatment, F(9, 171) = 1.468,/? = .213.
On reversal Day, all treatment groups exhibited decreased time spent in the
periphery of the pool across trials, F(9, 153) = 6.775, p < .01. There was also a main
effect of drug, F(3, 17) = 4.809,/? < .05 (Fig. 3.6b). There was found to be no significant
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Figure 3.5 Total distance (cm) traveled in the water maze on Acquisition day (A)
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M).
Each point represents group mean data for each of 10 trials immediately following
injection. Error bars represent + SEM. PPA-treated rats traveled significantly
greater distances on Acquisition day. On Reversal day, groups receiving PPA
traveled significantly larger distances across trials than controls, regardless of initial
drug treatment.
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Figure 3.6 Time spent in the periphery (s) of the water maze on Acquisition day (A)
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M).
Each point represents group mean data for each of 10 trials immediately following
injection. Error bars represent + SEM. The periphery represents the outer third of
the pool. On Acquisition day, PPA-treated rats spent more time in the periphery
compared to controls. On Reversal day, there was a main effect of drug treatment
on the amount of time spent in the periphery.
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interaction between trial and drug treatment, F(27, 153) = 1.122,p = .364, indicating that
the improvement across trials was similar across drug groups.
3.3.3.6 Number o f Direct and Circle Swims. As shown in Fig. 3.7a, during
acquisition training the PPA-treated group exhibited fewer direct and circle swim paths
than PBS controls. ANOVA confirmed this impression, revealing a significant drug
treatment effect, F( 1, 19) = 6.494,/? < .05, with the PPA group displaying fewer direct and
circle swims than PBS controls.
During reversal training, there was a significant main effect of group, F(3, 17) =
5.537,/?<.01 (Fig. 3.7b).
3.3.4 Neuropathological Data
3.3.4.1 Reactive Astrocytes. Coronal sections from three different brain areas
(dentate gyrus, dorsal hippocampus - CA2 region, and white matter) were stained with
glial fibrillary acidic protein (GFAP), which is a marker for reactive astrocytes. There was
a significant main effect o f drug treatment on GFAP staining in the white matter, F{3, 22)
= 5.779, p < .01. There were no significant group differences in the dentate, F(3, 22) =
2.310,/? = .104, or in the hippocampus, F(3, 22) = .816,/? = .499 (Fig. 3.8).
3.3.4.2 Activated Microglia. Sections from the same brain areas mentioned above
were also stained for Iba-1, a marker for activated microglia. There were no significant
group differences in any of the brain areas analyzed (Fig 3.9).
3.4 Discussion
This study examined the effects of nonspatial pretraining on water maze
performance following PPA infusion. It was found that PPA loading (i.e., ICV infusion

93

Figure 3.7 Number of direct and circle swims on Acquisition day (A) and on
Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). Each
bar represents group mean data immediately following injection. Error bars
represent + SEM. * p < .05. Rats treated with PPA exhibited significantly fewer
direct and circle swims than controls. On reversal day, there was found to be a
significant main effect of drug treatment on the number of direct and circle swims.
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Figure 3.8 Glial fibrillary acidic protein (GFAP) staining for rats injected with either
PBS (vehicle) or PPA (0.26M). GFAP is a marker for reactive astrocytes. Three
different brain areas were assessed: the dentate, the CA2 region of the
hippocampus, and white matter. Each point represents group mean data. Error
bars represent + SEM. * Refers to a significant group difference in the total mean
area stained by GFAP in the white matter, with PPA-PPA and PPA-PBS groups
showing significantly more staining than the PBS-PBS group.
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Figure 3.9 lba-1 staining for rats injected with either PBS (vehicle) or PPA (0.26M).
lba-1 is a marker for activated microglia. Three different brain areas were assessed:
the dentate, the CA2 region of the hippocampus, and white matter. Each point
represents group mean data. Error bars represent + SEM. There were no group
differences in the total mean area stained by lba-1.
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twice a day for seven days) was sufficient to severely disrupt cognitive functioning as
measured in the water maze (see Chapter 2). Not only did PPA treatment interfere with
water maze acquisition, but it was also found that two infusions of the compound alone
were sufficient to affect the animals’ ability to reverse the maze. While it was concluded
that the cognitive effects caused by PPA were not entirely permanent, as animals given
vehicle on reversal day were able to perform as well as controls, it was still necessary to
dissociate the two possible water maze processes that may have been affected by PPA
treatment. Successful water maze performance involves first learning the behavioural
strategies necessary to solve the maze, then learning the actual spatial location of the
platform in the maze. Nonspatial pretraining allows the animals to gain experience in the
former, without being trained for the latter (Morris, 1989). This previous experience
allows for the dissociation o f the two components when interpreting the findings.
3.4.1 Water Maze Acquisition
Pretrained rats subsequently treated with PPA had difficulty acquiring the maze.
They exhibited longer search latencies, greater total distances traveled, more time spent in
the periphery of the pool, and fewer direct and circle swims compared to pretrained
controls. Together, these findings indicate that even when animals have been nonspatially
pretrained in the maze, PPA treatment still had an effect on the cognitive processes
measured in the water maze. Search latencies during pretraining, combined with the
significant improvement in performance across trials during pretraining, suggest that all
animals were able to learn these behaviours throughout the pretraining trials. Following
the seven days o f infusions, the PPA-treated animals were not able to perform at the same
level as controls, even when nonspatially pretrained. Interestingly, a significant effect of
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pretraining on strategies used was observed, wherein pretrained groups (given PBS or
PPA) showed more direct and circle swims compared to non-pretrained groups (F(\, 33) =
29.035 , p < .001). This demonstrates that PPA-treated rats retained some aspects of their
nonspatial pretraining, yet still remained at a lower level of performance than controls.
Due to the lack o f significant group differences in swim speed (data not shown), this
deficit is likely not a result of motor impairments caused by PPA treatment. This pattern
of impairment, even after nonspatial pretraining, has rarely been reported. A study by
Morris (1989) reported that chronic administration of D,L-2-amino-5-phosphonopentanoic
acid (AP5, a potent and selective NMDA receptor antagonist) during water maze
acquisition training caused pretrained AP5 rats to exhibit shorter search latencies than
non-pretrained AP5 rats. However, the pretrained AP5 rats in this study still performed at
a lower level than controls. Morris (1989) concluded that pretraining decreased the
sensorimotor deficits caused by the drug, but had no effect on the drug-induced spatial
learning impairment in the maze.
Saucier et al. (1996) investigated the effects of NMDA antagonism on water maze
performance. It was found that naive (i.e., non-pretrained) drug-treated rats showed
certain sensorimotor disturbances that were not seen in control rats. These disturbances
included swimming excessively in the periphery, jumping or deflecting off of the
platform, and swimming over the platform rather than mounting it. These behaviours
were thought to have been the result of hyperactivity caused by the antagonist and would
have increased the search latencies exhibited by this group. Their data suggest that as
sensorimotor disturbances increase, maze acquisition scores decrease (Saucier et al.,
1996). Based on these findings, it would be wise to thoroughly investigate any
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sensorimotor disturbances that may be present in PPA-treated rats. It has been shown that
PPA can cause both hyperactivity and motor abnormalities (MacFabe et al., 2007,
MacFabe et ah, 2008), and so it is possible that this could have presented as sensorimotor
disturbances such as those reported by Saucier et ah (1996), causing impairments in
overall acquisition. A significant main effect of group was seen in the amount of time
spent in the periphery o f the pool on acquisition day, suggesting that the inefficient
strategy of thigmotaxic swimming in these animals could have been responsible for their
inferior performance in the maze. There was also observational evidence of other
sensorimotor dysfunction in these animals, such as platform swimovers and jumping off of
the platform, but these data were not quantified for the purposes o f the present study.
Findings by Saucier et ah (1996) and Morris (1989) suggest that these sensorimotor
deficits may have been a causal factor in the impairments seen in the maze, even following
pretraining. Deficits seen in the present study may have been the result of PPA-induced
sensorimotor disturbances rather than a specific spatial learning deficit, similar to what
was seen by Saucier et ah (1996).
Overall, rats in the present study were still unable to acquire the maze, even though
they had learned the necessary behavioural strategies beforehand in nonspatial pretraining.
Although PPA-treated rats were impaired on many measures in the maze, they did exhibit
a higher percentage of direct and circle swims compared to naive (non-pretrained) PPAtreated rats from Experiment 1 (see Chapter 2). This indicates that they were able to apply
some of the behavioural strategies acquired in pretraining.
3.4.2 Water Maze Reversal
During reversal of the maze, findings were less clear-cut. Rats treated with PPA on
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reversal day were impaired compared to controls on measures of search latency, total
distance traveled, and percentage of direct and circle swims. Interestingly, rats in either
the PBS-PPA or PPA-PPA groups were intermediate in their level of performance on
certain measures, as was seen in search latencies and time spent in the periphery,
respectively. This might indicate that, while two infusions of PPA were sufficient to cause
impairments on most measures, two infusions were not sufficient to cause impairments in
search latencies or periphery swimming when the animals had experience in the maze.
Again on reversal day, as in Experiment 1 (see Chapter 2), there was no main effect
of group on the percentage o f first choices made to the initial quadrant (data not shown).
This suggests that the animals were not impaired due to perseveration in returning to the
initial location of the platform, as was reported by Shultz et al. (2009). The current study
was designed to investigate the lasting effects of PPA on cognition. Shultz et al. (2009)
provided evidence that brief ICV administration of PPA caused perseveratory behaviours
that interfered with the animals’ ability to reverse the water maze. As animals in the
present study failed to acquire the maze to begin with, it was not possible to determine
whether or not they exhibited perseveratory behaviours later on in the experiment, using
the current experimental design.
3.4.3 Convulsive Activity
Several animals displayed convulsive activity in the water maze during acquisition.
Due to the nature o f the task and the potential interference that convulsive activity may
have caused in the animals’ ability to learn the maze, data from these five rats (out of a
total of 26 rats) was removed from all water maze analyses. Although the presence of
convulsive activity does not guarantee the occurrence of seizure activity, these data were
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removed to be conservative. One caveat is that in removing data from rats that displayed
convulsions, the data that were included in the analyses in essence came from animals that
were resistant to PPA-induced convulsions. Animals that were resistant to the
demonstrated electrophysiological effects of PPA (MacFabe et al., 2007) were selected for
in this analysis and this cannot be ruled out as a potential confound. A subgroup of these
rats is more sensitive to PPA on a number of behavioural and pathological variables
(MacFabe - personal communications), as is the case in human populations. Similarly,
although many animals did not exhibit outward signs of convulsive activity, this does not
necessarily mean that they did not experience seizure activity (e.g., immobility associated
with hippocampal seizures). This can only be confirmed electroencephalographically.
3.4.4 Open Field
Animals treated with PPA showed increased distances traveled and increased
average velocities compared to controls on the seventh day of infusions (acquisition day).
This is suggestive o f hyperactivity, which is consistent with previous studies using the
PPA rodent model o f ASD (MacFabe et al., 2007; MacFabe et al., 2008; Thomas et al.,
2010). Interestingly, there was no difference in the amount of time spent in the periphery
of the arena based on drug treatment. This is inconsistent with previous findings of
increased anxiety in the model (MacFabe et al., 2007; MacFabe et al., 2008; Shultz et al.
2008). Thigmotaxis, spending time in the periphery o f an arena or pool, is commonly
viewed as a measure of anxious behaviour in rodents. Animals given PPA did not exhibit
increases in this anxiety-related behaviour compared to controls. This finding was
inconsistent with the findings from Chapter 2, where PPA animals spent significantly
more time in the periphery of the open field apparatus compared to controls on acquisition
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day. This may have been a result of the vast amount of handling that the animals had
experienced by this point in the present experiment, which included a day of pretraining in
the maze that animals in the previous study did not experience. It is possible that the
animals were so habituated to experimental procedures by this seventh day of
experimentation that they no longer felt increased levels of anxiety compared to controls.
On reversal day, there were no group differences on any o f the variables measured in
the open field apparatus. This indicates that, regardless of initial drug treatment during
Phase I, one infusion of PPA was not sufficient to cause hyperactivity or anxiety on
reversal day. The lack o f significant group differences also suggests that the effects seen
on acquisition day as a result of PPA loading did not persist during the week of
“recovery”. This may indicate that the effects seen on acquisition day were not permanent
and were able to be returned to baseline over time, once PPA treatment had been stopped.
3.4.5 Neuropathological Data
There was a significant increase in reactive astrocytes in the white matter of rats
from the PPA-PPA and PPA-PBS groups, compared to controls. Reactive astrogliosis in
animals from the PBS-PPA group was not found to be significantly different than any
other group. These findings suggest that PPA loading (i.e., two infusions per day for
seven days) causes persistent astroglial inflammation, even after a week of no infusions.
According to Vargas et al. (2005), post-mortem studies of brain tissue of autistic patients
showed increased levels o f GFAP immunostaining relative to controls in the three regions
of the brain that were examined: dorsal hippocampus and adjacent white matter of the
external capsule. The most marked astroglial reactivity was seen in the granular cell layer
of the cerebellum, as well as the cerebellar white matter. Overall, the authors concluded
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that there is an innate neuroinflammatory response present in the brains of autistic
patients, characterized by activation of microglial and astroglial cells in the cerebral cortex
and the cerebellum (Vargas et al., 2005). A significant group difference in microglial
activation was not found in the present study. The lack of significant group differences on
this measure could signify that there was no activation of microglia as a result of PPA
infusion. MacFabe and colleagues (2007; 2008), however, found significant microglial
and astroglial activation in the brain tissue of rats that had been infused with 0.26M PPA
twice a day for thirteen consecutive days, and then sacrificed immediately. This suggests
that the lack of group differences in the present study was not indicative of the absence of
microglial activation altogether, but rather evidence for microglial “recovery” following
the cessation o f PPA treatment, as activation o f microglia has been well documented in the
model.
Overall, the neuropathological findings in the present study suggest that the majority
of the inflammation caused by PPA infusion (MacFabe et al., 2007; MacFabe et al., 2008)
returns statistically to baseline after one week of no infusion, with the exception of
astrogliosis in the white matter of these animals, which seems to persist. Due to the
present lack o f research on recovery in ASD, as well as the nature of post-mortem studies,
the innate neuroinflammatory response characteristic of ASD has not yet been explored in
“recovered” patients. The current findings suggest, however, that this pattern of
inflammation may return to baseline after cessation of PPA treatment.
3.4.6 Return to Baseline After Cessation o f PPA Treatment
The purpose of this study was to examine the effects of nonspatial pretraining on the
ability of PPA-treated rats to acquire the Morris water maze and whether or not the
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observed cognitive deficits caused by PPA would return to baseline after drug treatment
had been discontinued. The concept of “recovery” in autism has not yet been extensively
studied and is just beginning to become an area of interest for ASD researchers. Though
the definition of “recovery” is varied and not widely agreed upon, Helt et al. (2008)
defined it as the loss o f the behavioural characteristics of ASD. They do not suggest that
these children recover to a state o f “normalcy”, but that they reach a level where they are
learning and applying new skills at an appropriate age and developmental level for that
child (Helt et al., 2008).
PPA treatment has been shown to cause behavioural, biochemical, and
neuropathological changes in rodents that are consistent with characteristics seen in ASD
(MacFabe et al., 2007, MacFabe et al., 2008; MacFabe et al., 2011; Shultz et al., 2008;
Shultz et al., 2009; Thomas et al., 2010). These widespread effects of PPA had not yet
been looked at on a long-term basis prior to the present study. By infusing rats with PPA
twice a day for seven days, and then allowing a week of “recovery”, where no PPA was
administered, it was possible to examine the effects of the initial PPA loading followed by
a period of PPA discontinuation. For the most part what was seen was a return to baseline
by these animals, on most variables measured in the open field, the water maze, and
histological analysis. Rats that were infused with PPA initially and then subsequently
infused with PBS vehicle on reversal day, after a seven-day period o f “recovery” showed
no impairments in the water maze or open field compared to controls. As groups
receiving PPA on reversal day were most often not significantly different, regardless of
initial drug treatment, it appears as though the effects of PPA loading are not permanent.
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4.1

“Recovery” in Autism Spectrum Disorders

Several studies have reported on the concept of “recovery” in autism. While ASDs
are generally considered to be life-long disorders affecting cognition, language, and social
behaviour, the severity o f these symptoms varies between individuals and also across time
within individuals (Helt et al., 2008). Herbert and colleagues (2006) noted that there is
substantial intra-individual variability in autistic individuals in both the nature and severity
of the characteristic symptoms, and this variability can occur over the short, medium, or
long term. Helt et al. (2008) describe “recovery” as the loss of the behavioural
characteristics of ASD, though they acknowledge that this most often does not result in the
child receiving a label o f “normal”. Beyond individual case studies o f recovery in autism,
the long-term outcome in terms of diagnostic stability has not been widely studied and the
findings that do exist are often varied. For instance, Cox et al. (1999) found that all nine
children studied who were diagnosed with pervasive developmental disorder (PDD, a
disorder on the autism spectrum) at 20 months of life retained the diagnosis at 42 months.
Other studies have reported that a subset of individuals achieved normal levels of
intellectual and educational functioning following intensive behavioural therapy over a
number o f years (McEachin, Smith, & Lovaas, 1993). Based on Helt et al.’s (2008)
definition of “recovery” as the loss of characteristic symptomatology, there have also been
reports of the improvement of ASD symptoms following the removal of certain wheat or
dairy products from the diet (Jyonouchi, Sun, & Itokazu, 2002). These limited yet
encouraging findings suggest that a diagnosis o f ASD is not necessarily retained in all
children over time.
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The purpose of the present studies was to investigate this idea of “recovery” using an
animal model o f ASD. Studies using the PPA rodent model of autism have shown
behavioural, neuropathological, and biochemical changes in animals resulting from
treatment with PPA, all of which are consistent with findings from autistic patients
(MacFabe et al,, 2007; MacFabe et al., 2008; MacFabe, Cain, Boon, Ossenkopp, & Cain,
2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). Shultz et al. (2009) in
particular found a unique pattern of perseveratory behaviour using the Morris water maze,
following PPA treatment. Animals were given three or five single, spaced infusions of
PPA and tested in the water maze for acquisition and then maze reversal. During reversal
training, they were unable to learn the new location of the hidden platform due to
persistent returning to the initial quadrant that held the platform during acquisition. Given
what is known about the various physiological effects of PPA in humans (Al-Lahham,
Peppelenbosch, Roelofsen, Vonk, & Venema, 2010; Hara, Haga, Aoyama, & Kiriyama,
1999; Nakao, Moriya, Furuyama, Niederman, & Sugiy, 1998; Wagner, Bayir, Ren,
Puccio, Zafonte, & Kochanek, 2004), as well as the effects seen in the rodent model of
autism, it was of interest to investigate the time-course of these effects and whether or not
they are permanent. Overall, the findings from the present studies suggest that the
majority of cognitive and neuropathological variables measured return to baseline levels
following cessation of PPA treatment. There were several instances where animals in
either the PPA-PBS or PBS-PPA group performed at an intermediate level between PBSPBS controls and PPA-PPA animals on reversal day, such as total distance traveled and
time spent in periphery for non-pretrained animals and search latency for pretrained
animals. These interesting findings suggest that there may be differential effects of PPA,
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based on the dose and timing of administration. In the case of the PPA-PBS group, these
intermediate values, though not statistically significant, might suggest a remaining deficit
left over from initial PPA treatment. The intermediate performance on some variables
seen in the PBS-PPA group, however, suggests that two infusions alone of PPA on
reversal day were not enough to cause the same severity of impairment as seen following
16 infusions o f the compound (in the case of the PPA-PPA group). This would indicate
that, perhaps there are persisting effects caused by PPA loading, which were not identified
using the present experimental design.
Further evidence for a return to baseline following cessation of PPA treatment came
from the finding o f a lack o f group differences in neuroinflammation in the brains of these
rodents. Other than an increase in reactive astrocytes seen in the white matter of
pretrained animals treated with PPA the day prior to perfusion, regardless o f initial
treatment, there were no observed differences in GFAP or Iba-1 staining in any other brain
area studied. Due to the known neuroinflammatory response in the PPA model of autism
(MacFabe et al., 2007; MacFabe et ah, 2008), it would be appropriate to cautiously
suggest a return to baseline in the inflammatory response of these glial cells following
cessation of treatment with PPA. It could be the case that the astroglial inflammation
induced in the white matter following acute treatment with PPA was more extensive than
the inflammation induced in other areas. It has been shown that ASD patients have an
increased white matter volume compared to controls (Herbert, 2005) and this could result
from an inflammatory response.
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4.1.1 Possible Mechanisms
The underlying mechanism(s) of the effects of PPA on various cognitive,
behavioural, and neuropathological effects is unknown. The effects seen in the current
study appear to return to baseline after a brief period of no infusion. This suggests, as has
been shown by other studies using the model (MacFabe et al., 2007), that many of the
effects of PPA are transient. The transient nature of these alterations implicates the action
of environmentally responsive disease mechanisms, which would also explain the
fluctuations seen in autistic symptomatology. As previously mentioned, it is possible that
PPA is affecting gene expression. MacFabe and colleagues (2007) found increased
immunoreactivity of the phosphorylated form o f cyclic AMP responsive binding protein
(pCREB), which, in its activated form, is involved in altering the expression of genes
involved in learning and memory. Beyond this, Herbert et al. (2006) found a number of
environmentally responsive genes that overlap with known autism linkage regions. This
set of genes included, but was not limited to, those involved in cell signaling, homeostasis,
metabolism, immune/inflammatory response, and oxidative stress/metabolism. Another
possible mechanism for these behavioural effects of PPA was highlighted in a study done
by Thomas and colleagues (2010) using the PPA model of autism. The authors found
alterations in the lipid profiles o f rodents who had been treated with PPA twice a day for
seven days that were consistent with alterations seen in the lipid profiles of autistic
patients (Bell, Sargent, Tocher, & Dick, 2000). Similarly, studies and anecdotal reports
from parents o f autistic children have suggested improvements in the general health and a
reduction in core symptoms in ASD patients following essential fatty acid
supplementation (Bell, MacKinlay, Dick, MacDonald, Boyle, & Glen, 2004; Richardson,
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2006). The lipids showing alterations in the PPA rodent model included those involved in
cell-to-cell signaling, membrane fluidity, and energy metabolism (Thomas et al., 2010).
Changes affecting the ability o f cells to communicate with one another (i.e., changes in
membrane fluidity, cell signaling, and the uncoupling of gap junctions) could all affect
processes involved in learning and memory, as was seen in the present experiments.
However, it is not clear precisely which of the diverse effects of SCFAs are responsible
for the observed characteristics in the model.
4.2 Limitations and Future Directions
While the current study has contributed to the PPA rodent model of autism by
beginning to investigate the time course of the effects of the compound, there is still a
great deal of work to be done in this area. As with any study, there were limitations,
leading to the inability to draw certain, definite conclusions from the collected data.
Identification of these limitations can help to interpret the data, as well as lead to further
areas of study using the model.
4.2.1 Convulsive Activity
Slightly less than one third of the animals in the two studies presented here displayed
convulsive activity in the water maze during acquisition. Due to the potential interference
that convulsive activity may have caused in the animals’ ability to learn the maze, data
from these rats were removed from all water maze analyses. Although the presence of
convulsive activity does not guarantee the occurrence of seizure activity, these data were
removed to be conservative. In removing these data, the remaining data that were
analyzed came from animals that were essentially resistant to PPA-induced convulsions.
Animals that were resistant to the demonstrated electrophysiological effects of PPA
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(MacFabe et al., 2007) were selected for in this analysis and this cannot be ruled out as a
potential confound. Similarly, although many animals did not exhibit outward signs of
convulsive activity, this does not necessarily mean that they did not experience seizure
activity. This can only be confirmed through EEG.
Future studies might address this issue by experimenting with a lower dose of PPA
that would cause fewer convulsions. The study by Shultz et al. (2009), which used three
or five single, spaced ICV infusions prior to testing, reported no convulsive activity during
water maze training. This suggests that altering the infusion schedule, either the frequency
or dose o f PPA administration, can potentially alter the level of convulsive activity seen in
the model. Flowever, the current studies employed the 7-day infusion schedule in order to
be consistent with the previous work done using the PPA rodent model of autism (Thomas
et al., 2010). Similarly, the occurrence of convulsive activity in these experiments lends
validity to the model in that seizure disorder and epilepsy are often comorbid with ASD
(Besag, 2004; Herbert et al., 2006) and other neurodevelopmental disorders, particularly
those involving more severe cognitive and/or developmental delay (Sunder, 1997). In
fact, it is possible that this electrophysiological activity that has been shown to occur in
these patients could be contributing to the cognitive deficits that are present in this
population.
4.2.2 Future Studies
Intracerebroventricular infusion of enteric SCFAs, such as PPA, in rodents is
becoming a promising animal model for investigating the various behavioural and
neuropathological aspects o f ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe
et al., 2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). The findings of
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the present study are consistent with ASD, and offer further support of PPA administration
as an animal model o f autism. Further work with the model should examine the time
course of the effects o f SCFAs in adolescent rats. ASD is a lifelong disorder, making it
important to study at various different points o f development. Similarly, it is necessary to
conduct further studies aimed at identifying possible mechanisms that are responsible for
these effects. Identification o f a mechanism would be a step towards isolating potential
biomarkers and eventually treatments for this disorder. Based on the promising findings
of altered lipid profiles in the model similar to those seen in ASD patients (Thomas et al.,
2010), future work should explore the lipid profiles over an extended time course, such as
the one used in the present studies. It would be interesting to see if the alterations in the
lipid profiles caused by PPA administration return to baseline after a period of time
without exposure to the compound in the same way that behavioural and
neuropathological alterations did in the present studies. These studies are ongoing using
brain tissue obtained from the present study. Overall, the PPA rodent model of autism has
proved to be a valid model for studying the disparate symptoms, comorbidities, and
biomarkers found in ASD, and there is a great deal more work that can be done to
continue to add to what is known about the disorder.
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